For O
treatment O
and O
management O
of O
epilepsy B-PHE
and O
seizures B-PHE
associated O
with O
Lennox-Gastaut B-PHE
syndrome I-PHE
, O
a O
difficult-to-treat O
form O
of O
childhood B-PHE
epilepsy I-PHE
. O

-DOCSTART- O


Hemophilia B-PHE
A I-PHE

-DOCSTART- O


sore B-PHE

-DOCSTART- O


general O
swelling B-PHE
and O
small B-PHE
amount I-PHE
urine I-PHE

-DOCSTART- O


1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-PHE
wounds I-PHE
with O
hemorrhage B-PHE
( O
topical O
use O
) O
. O

2 O
Applicable O
to O
cases O
of O
angina B-PHE
pectoris I-PHE
which O
are O
attributive O
to O
retention O
of O
blood B-PHE
stasis I-PHE
. O

3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O


Hypertension B-PHE
, O
kidney B-PHE
vacuity I-PHE
lumbago I-PHE
, O
weakness B-PHE
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O


ADHD B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


excessive B-PHE
thought I-PHE
; O
anxiety O

-DOCSTART- O


To O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-PHE
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
chronic B-PHE
coughing I-PHE
and O
inflammation B-PHE
in O
urination O
. O

-DOCSTART- O


Intelligence B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


a O
symptom O
of O
having O
muscular B-PHE
flaccidity I-PHE
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-PHE
of I-PHE
nourishment I-PHE
in O
organs O
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-PHE
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-PHE
cell I-PHE
phagocytosis I-PHE
. O

Anti-inflammation B-PHE
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O


To O
move O
qi O
, O
precipitate O
qi O
, O
relieve O
pain B-PHE
, O
disperse O
distention O
, O
free O
milk O
. O

-DOCSTART- O


Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 O
relaxation O
time O
, O
thus O
producing O
an O
increase O
in O
signal O
intensity O
. O

Gadodiamide O
does O
not O
cross O
the O
intact O
blood-brain B-PHE
barrier I-PHE
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
lesions B-PHE
that O
have O
not O
caused O
an O
abnormal O
blood-brain B-PHE
barrier I-PHE
( O
e.g O
. O
, O
cysts B-PHE
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-PHE
vascularity I-PHE
or O
disruption B-PHE
of I-PHE
the I-PHE
blood-brain I-PHE
barrier I-PHE
allows O
accumulation O
of O
gadodiamide B-PHE
in I-PHE
lesions I-PHE
such O
as O
neoplasms B-PHE
, O
abscesses B-PHE
, O
and O
subacute B-PHE
infarcts I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
regurgitation B-PHE

-DOCSTART- O


Inhibited O
urination B-PHE
, O
dribbling O
pain B-PHE
of O
urination O
, O
edema B-PHE
, O
bloody B-PHE
urine I-PHE
, O
damp-heat B-PHE
dysentery I-PHE
, O
asthma B-PHE
, O
sore B-PHE
swollen I-PHE
throat I-PHE
, O
toxin B-PHE
swelling I-PHE
of O
sores O
, O
wind-damp B-PHE
pain I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
bleeding B-PHE
knife O
wound O
. O

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
bloat I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


swelling B-PHE
and O
bearing-down B-PHE
pain I-PHE
of O
unilateral O
testis O
; O
unilateral O
swelling B-PHE
of I-PHE
the I-PHE
testis I-PHE

-DOCSTART- O


Boils B-PHE
and O
carbuncles B-PHE
. O

-DOCSTART- O


release O
the O
exterior O
and O
dispel O
wind B-PHE

-DOCSTART- O


Treatment O
of O
weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
lung I-PHE
manifested O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
, O
palpitation B-PHE
, O
anorexia B-PHE
, O
loose B-PHE
stools I-PHE
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
. O

-DOCSTART- O


inflammation B-PHE
of O
the O
throat O
; O
sore B-PHE
throat I-PHE
; O
hoarse B-PHE
voice I-PHE
; O
aphonia B-PHE

-DOCSTART- O


Its O
aqueous O
infusion O
inhibits O
the O
growth B-PHE
of I-PHE
skin I-PHE
fungi I-PHE
such O
as O
Trichophyton B-PHE
violaceum I-PHE
. O

-DOCSTART- O


To O
enrich O
the O
blood B-PHE
, O
to O
activate O
blood B-PHE
circulation I-PHE
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O


Chronic B-PHE
Fatigue I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
following O
mild-to-moderate B-PHE
infections I-PHE
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-PHE
bacterial I-PHE
exacerbations I-PHE
of I-PHE
chronic I-PHE
bronchitis I-PHE
, O
secondary B-PHE
bacterial I-PHE
infection I-PHE
of O
acute B-PHE
bronchitis I-PHE
, O
community B-PHE
- I-PHE
acquired I-PHE
pneumonia I-PHE
, O
pharyngitis B-PHE
/ O
tonsilitis B-PHE
, O
and O
uncomplicated B-PHE
skin I-PHE
and O
skin B-PHE
structure I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from O
the O
lung O
and O
relieve O
sore B-PHE
throat I-PHE
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
water O
and O
disperse O
edema B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
. O

-DOCSTART- O


post B-PHE
delivery I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Woman O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE
, O
Others O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Hemostatic B-PHE
function I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


pull O
up O
toxicity B-PHE
and O
regenerate O
flesh B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
of O
a O
retarded B-PHE
child I-PHE
. O

There O
are O
five O
symptoms O
including O
slow B-PHE
stand I-PHE
, O
delayed O
development O
in O
walking O
, O
retardation O
in O
hair-growing O
, O
delayed B-PHE
development I-PHE
in O
growth O
of O
teeth O
, O
and O
delayed B-PHE
development I-PHE
of O
speech O
in O
an O
infant O
. O

-DOCSTART- O


Pulmonary O
Aspiration O

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
reinforce O
blood B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
; O
hemostasis B-PHE

-DOCSTART- O


freckles B-PHE
on O
face O

-DOCSTART- O


Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-PHE
of I-PHE
neutrophils I-PHE
in O
the O
bone O
marrow O
. O

-DOCSTART- O


Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene B-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased B-PHE
cell I-PHE
proliferation I-PHE
, O
and O
inhibition B-PHE
of I-PHE
tumorigenesis I-PHE
. O

-DOCSTART- O


Heart B-PHE
Failure I-PHE
. O

-DOCSTART- O


juvenile O
onset O
smallpox B-PHE
poison O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation B-PHE

-DOCSTART- O


pain B-PHE
in O
ear O

-DOCSTART- O


Numbness B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
aching B-PHE
of O
the O
joints O
and O
menstrual B-PHE
disorders I-PHE
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
fullness B-PHE
and I-PHE
pain I-PHE
in I-PHE
the I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O


Treatment O
of O
hemoptysis B-PHE
, O
hematemesis B-PHE
, O
epistaxis B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
pricking O
pain B-PHE
in O
the O
chest O
and O
abdomen O
, O
traumatic B-PHE
swelling I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O


deficiency B-PHE
and I-PHE
chills I-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


frequent B-PHE
vomiting I-PHE

-DOCSTART- O


epigastric O
twisting O
pain B-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
protease I-PHE
enzyme I-PHE
. O

-DOCSTART- O


Statin O
Therapy O

-DOCSTART- O


TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin O
, O
a O
potent O
mediator O
of O
blood O
vessel O
constriction O
and O
growth O
of O
smooth O
muscle O
in O
vascular B-PHE
walls I-PHE
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-PHE
arterial I-PHE
hypertension I-PHE
. O

TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O


insulin O
sensitivity O
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Quality O
of O
life O
, O
Menopausal B-PHE
woman O
, O
Eldery O
, O
Liver B-PHE
health I-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Bone B-PHE
metabolism/density B-PHE
, O
Memory O
, O
Liver O
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


swelling B-PHE
of O
the O
foot O
; O
edema B-PHE
of O
foot O

-DOCSTART- O


Obesity B-PHE
and O
Obesity-related B-PHE
Medical O
Conditions O

-DOCSTART- O


frost B-PHE
bite I-PHE
; O
chilblain B-PHE
; O
frostbite B-PHE

-DOCSTART- O


Migraine B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
taxation O
damage O
in O
lumbar B-PHE
muscle I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Stage O
IV O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
heparin-induced B-PHE
thrombocytopenia I-PHE

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


For O
cooling O
blood B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


chest O
and O
hypochondriac O
pain O

-DOCSTART- O


This O
is O
bleeding B-PHE
due O
to O
an O
external B-PHE
wound I-PHE
. O

-DOCSTART- O


glad O
and O
misten B-PHE
complexion I-PHE

-DOCSTART- O


Treatment O
of O
taeniasis B-PHE
, O
ancylostomiasis B-PHE
, O
ascariasis B-PHE
, O
intestinal B-PHE
parasitosis I-PHE
with O
abdominal B-PHE
pain I-PHE
or O
with O
infantile B-PHE
malnutrition I-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
subcutaneous I-PHE
nodes I-PHE

-DOCSTART- O


For O
desolving O
phlegm B-PHE
, O
stopping O
cougth B-PHE
, O
and O
soothing O
breathing B-PHE

-DOCSTART- O


Roundworm B-PHE

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


fever B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-PHE
colorectal I-PHE
carcinoma I-PHE
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O


Rheumatism B-PHE
numbness I-PHE
, O
damp-heat B-PHE
itchy I-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
menstruant O
morbidity O
. O

-DOCSTART- O


To O
soothe O
the O
liver B-PHE
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-PHE
and O
toxic O
materials O
. O

-DOCSTART- O


new O
and O
old O
cough B-PHE

-DOCSTART- O


To O
supplement O
blood B-PHE
and O
quicken O
blood B-PHE
, O
free O
channels B-PHE
and O
quicken O
network B-PHE
vessels I-PHE
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Edema B-PHE
due O
to O
deficiency B-PHE
in I-PHE
the I-PHE
kidney I-PHE
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-PHE
and O
cough B-PHE
. O

-DOCSTART- O


leukorrhea B-PHE
with O
pruritis B-PHE
vulva I-PHE

-DOCSTART- O


Liver O
Transplantation O

-DOCSTART- O


To O
regulate O
menstruation B-PHE
, O
replenish O
blood B-PHE
and O
regulate O
qi O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


To O
supplement O
blood B-PHE
, O
quicken B-PHE
blood I-PHE
, O
strengthen O
lumbus B-PHE
and O
knees B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
abdominal B-PHE
distension I-PHE
and O
pain B-PHE
caused O
by O
retention O
of O
undigested O
food O
. O

-DOCSTART- O


To O
eliminate O
toxic B-PHE
material I-PHE
, O
promote O
pus B-PHE
drainage I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Papillary B-PHE
serous I-PHE
endometrial I-PHE
cancer I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE
, O
Pediatric O

-DOCSTART- O


1 O
To O
remove O
blood B-PHE
stasis I-PHE
and O
alleviate O
pain B-PHE
. O

For O
stomachache B-PHE
, O
headache B-PHE
, O
toothache B-PHE
, O
trauma B-PHE
and O
rheumatism O
. O

2 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
. O

For O
sorethroat B-PHE
, O
aphthae B-PHE
, O
carbuncle B-PHE
, O
burn B-PHE
, O
snake B-PHE
bite I-PHE
, O
dysentery B-PHE
and O
diarrhea B-PHE
. O

3 O
To O
relax O
the O
muscles O
. O

As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-PHE
and O
surgical O
operation O
. O

-DOCSTART- O


Chloramphenicol O
reversibly O
binds O
to O
the O
L16 B-PHE
protein I-PHE
of O
the O
50S B-PHE
subunit I-PHE
of I-PHE
bacterial I-PHE
ribosomes I-PHE
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase B-PHE
I I-PHE
, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular B-PHE
DNA I-PHE
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-PHE
molecules I-PHE
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human B-PHE
mucosa I-PHE
. O

-DOCSTART- O


pulmonary B-PHE
carbuncle I-PHE
; O
lung B-PHE
abscess I-PHE

-DOCSTART- O


a O
disease O
that O
tendons B-PHE
and O
bones B-PHE
become O
dry O

-DOCSTART- O


vomiting B-PHE

-DOCSTART- O


Yang O
poison B-PHE
; O
extreme O
heat B-PHE
; O
symptoms O
due O
to O
extreme O
heat B-PHE

-DOCSTART- O


the O
steaming B-PHE
of I-PHE
bone I-PHE
and O
tidal O
fever B-PHE

-DOCSTART- O


1 O
Byak-angelicin O
contained O
in O
its O
root O
can O
dilate O
the O
coronary B-PHE
arteries I-PHE
. O

2 O
Stimulating O
the O
respiratory B-PHE
center I-PHE
, O
vasomotor B-PHE
center I-PHE
and O
nervus B-PHE
vagus I-PHE
. O

3 O
Its O
decoction O
exerts O
bacteriostatic B-PHE
effect I-PHE
. O

4 O
Imperatorin O
, O
another O
active O
component O
, O
is O
effective O
for O
psoriasis B-PHE
. O

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Others O

-DOCSTART- O


Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard B-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


To O
pacify O
the O
liver B-PHE
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-PHE
; O

To O
stop O
bleeding B-PHE

-DOCSTART- O


gingivitis B-PHE
; O
epulis B-PHE

-DOCSTART- O


kill O
worms B-PHE

-DOCSTART- O


HER2-overexpressing O
breast B-PHE
cancer I-PHE

-DOCSTART- O


ischuria B-PHE
; O
dysuria B-PHE
; O
retention B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Juzentaihoto O
Failed O
to O
Augment O
Antigen-Specific O
Immunity B-PHE
but O
Prevented O
Deterioration B-PHE
of O
Patients' O
Conditions O
in O
Advanced O
Pancreatic B-PHE
Cancer I-PHE
under O
Personalized O
Peptide O
Vaccine O
. O

-DOCSTART- O


To O
break O
blood B-PHE
and O
desolve O
stagnation B-PHE
; O
To O
benefit O
qi O

-DOCSTART- O


Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme B-PHE
acetylcholinesterase I-PHE
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-PHE
disease I-PHE
. O

-DOCSTART- O


Effects O
of O
Hachimijiogan O
on O
dopamine O
, O
serotonin O
and O
vasoactive O
intestinal O
peptide O
in O
plasma O
and O
hypothalamus O
in O
sulpiride-induced O
hyperprolactinemic O
rats O
. O

-DOCSTART- O


Chronic B-PHE
Heart I-PHE
Failure I-PHE

-DOCSTART- O


Treatment O
of O
carbuncle B-PHE
and O
boil B-PHE
at O
the O
early O
stage O
or O
formation B-PHE
of I-PHE
abscess I-PHE
difficult O
to O
burst B-PHE
, O
external O
use O
for O
scabies B-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


oppressed B-PHE
feeling I-PHE
and O
fullness B-PHE
in O
the O
chest O
and O
diaphragm O

-DOCSTART- O


Spontaneous O
external B-PHE
bleeding I-PHE
, O
hematochezia B-PHE
, O
headache B-PHE
, O
dizziness B-PHE
and O
dim B-PHE
vision I-PHE
, O
red B-PHE
eyes I-PHE
, O
night B-PHE
blindness I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
fecal B-PHE
stoppage I-PHE
, O
hemorrhoids B-PHE
. O

-DOCSTART- O


warm B-PHE
malaria I-PHE
; O

pyrexial B-PHE
malaria I-PHE

-DOCSTART- O


Enduring O
cough B-PHE
and O
asthma B-PHE
, O
bronchitis B-PHE
, O
lumbago B-PHE
and O
limp O
leg B-PHE
, O
frequent O
urination B-PHE
, O
enuresis B-PHE
, O
impotence B-PHE
, O
emission B-PHE
, O
intestinal B-PHE
dry I-PHE
and O
constipation B-PHE
, O
stone B-PHE
strangury I-PHE
, O
sores B-PHE
and O
scrofula B-PHE
. O

-DOCSTART- O


Cancer B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
effuse O
sweat B-PHE
, O
dissipate O
cold B-PHE
and O
dry O
damp B-PHE
. O

-DOCSTART- O


snake-bite B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


To O
astringe O
intestines B-PHE
and O
check O
diarrhea B-PHE
, O
resolve O
toxin B-PHE
, O
relieve O
itch B-PHE
. O

-DOCSTART- O


Ritonavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
proteinase I-PHE
enzyme I-PHE
which O
prevents O
cleavage B-PHE
of I-PHE
the I-PHE
gag-pol I-PHE
polyprotein I-PHE
, O
resulting O
in O
noninfectious O
, O
immature O
viral B-PHE
particles I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
aching B-PHE
pain I-PHE
in O
joints O
, O
arthritis B-PHE
, O
dysmenorrhea B-PHE
, O
skin B-PHE
numbness I-PHE
, O
weakness B-PHE
in I-PHE
limbs I-PHE
, O
jaundice B-PHE
, O
cough B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
sores B-PHE
, O
zoster B-PHE
, O
scalds B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hemorrhoids B-PHE
( O
2 O
) O
polyp B-PHE

-DOCSTART- O


damp B-PHE
Pi O
arthritis B-PHE
due O
to O
dampness B-PHE
. O

damp B-PHE
stroke I-PHE
; O

attack O
of O
dampness B-PHE
syndrome I-PHE
due O
to O
attack O
of O
pathogenic B-PHE
factors I-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
the O
growth O
of O
leukemia615 B-PHE
, O
sarcoma180 B-PHE
and O
cervial B-PHE
carcinoma14 I-PHE
in O
mice O
. O
2 O
Relieving O
iodine B-PHE
deficiency I-PHE
and O
goiter B-PHE
in O
experimental O
animals O
. O

-DOCSTART- O


swelling B-PHE
of O
the O
cheek O
; O
parotitis B-PHE

-DOCSTART- O


Bone B-PHE
Marrow I-PHE
Suppression I-PHE

-DOCSTART- O


Eum O
deficiency O
of O
liver O
and O
kidney O
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver O
and O
kidney O

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE

-DOCSTART- O


Chronic B-PHE
Viral I-PHE
Hepatitis I-PHE
B I-PHE
Without I-PHE
Delta-agent I-PHE

-DOCSTART- O


prolapse B-PHE
of I-PHE
the I-PHE
rectum I-PHE

-DOCSTART- O


Hypertension B-PHE
. O

-DOCSTART- O


Menopausal B-PHE
syndrome I-PHE
marked O
by O
afternoon O
fever B-PHE
, O
excessive B-PHE
sweating I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
insomnia B-PHE
and O
unsteady B-PHE
blood I-PHE
pressure I-PHE
. O

-DOCSTART- O


Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O


nausea B-PHE
without O
vomiting B-PHE
. O

-DOCSTART- O


1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-PHE
and O
decrease O
the O
level B-PHE
of I-PHE
cGMP I-PHE
in O
plasma O
and O
in O
leukocytes O
. O
Protect O
the O
liver B-PHE
from O
damage O
. O
Hypotensive B-PHE
. O

-DOCSTART- O


Drug B-PHE
Induced I-PHE
Hepatotoxicity I-PHE

-DOCSTART- O


12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-PHE
component I-PHE
. O

-DOCSTART- O


To O
desolve O
phlegm B-PHE
and O
soften O
hardness O
; O
To O
revitalize O
blood B-PHE

-DOCSTART- O


Some O
patients O
with O
major B-PHE
depressive I-PHE
disorder I-PHE
( O
MDD B-PHE
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
associated O
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-PHE
or O
weakness B-PHE
of O
the O
lower O
abdomen O
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O


Treament O
of O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Kidney B-PHE
Diseases I-PHE

-DOCSTART- O


Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-PHE
sensation I-PHE
and O
numbness B-PHE
after O
stroke B-PHE
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke B-PHE
patients O
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
bladder B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


Thoracic O
Surgery O

-DOCSTART- O


wind B-PHE
syndrome I-PHE

-DOCSTART- O


Carotid B-PHE
Artery I-PHE
Stenosis I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


Infant B-PHE
, I-PHE
Diabetic I-PHE
Mother I-PHE

-DOCSTART- O


Treament O
of O
heat B-PHE
in O
the O
lung O
with O
cough B-PHE
, O
sticky B-PHE
and I-PHE
bloody I-PHE
sputum I-PHE
, O
and O
distress B-PHE
in I-PHE
the I-PHE
chest I-PHE
. O

-DOCSTART- O


HGS-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-PHE
and O
has O
anti-tumor B-PHE
activity I-PHE
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGS-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody B-PHE
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-PHE
human I-PHE
tumors I-PHE
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-PHE
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O


Tiagabine O
blocks O
GABA O
uptake O
into O
presynaptic O
neurons O
, O
permitting O
more O
GABA O
to O
be O
available O
for O
receptor O
binding O
on O
the O
surfaces O
of O
post-synaptic O
cells O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated O
N-type O
calcium O
ion O
channels O
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent O
calcium O
channel O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

-DOCSTART- O


wind B-PHE
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease B-PHE
in O
association O
with O
other O
pathogenic O
agent O
. O

It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic O
material O
. O

2 O
To O
clear O
liver-heat B-PHE
to O
treat O
eye B-PHE
disease I-PHE
. O

3 O
To O
clear O
dampness-heat B-PHE
. O

-DOCSTART- O


Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O


exogenous O
exogenous B-PHE
febrile I-PHE
disease I-PHE
; O

syndrome B-PHE
of I-PHE
T'aeyang I-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE

affection O
by O
cold B-PHE
; O

common B-PHE
cold I-PHE

-DOCSTART- O


Glomerulonephritis O

-DOCSTART- O


blurred B-PHE
vision I-PHE

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
qi O
; O
To O
soothe O
liver B-PHE
and O
modulate O
qi O
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Treament O
of O
abdomen B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
worms I-PHE
, O
sores B-PHE
, O
uterine B-PHE
bleeding I-PHE
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O


irregular O
chills B-PHE
and I-PHE
fever I-PHE

-DOCSTART- O


unblock O
blood B-PHE

-DOCSTART- O


Treatment O
of O
chills B-PHE
, O
fever B-PHE
and O
headache B-PHE
in O
colds B-PHE
and O
influenza B-PHE
, O
vexation B-PHE
, O
oppressed B-PHE
feeling I-PHE
in O
the O
chest O
and O
insomnia B-PHE
. O

-DOCSTART- O


Kidney B-PHE
Failure I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


This O
is O
an O
external B-PHE
wound I-PHE
in I-PHE
muscle I-PHE
of I-PHE
waist I-PHE
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute B-PHE
hepatitis I-PHE
with O
jaundice B-PHE
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
activities I-PHE
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
infections I-PHE
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-PHE
than O
against O
HSV-1 B-PHE
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-PHE
infection I-PHE
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-PHE
infection I-PHE
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-PHE
infectivity I-PHE
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection B-PHE
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections B-PHE
by O
HSV-1 B-PHE
and O
HSV-2 B-PHE
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-PHE
infectivity I-PHE
. O

-DOCSTART- O


red-white O
dysentery B-PHE

-DOCSTART- O


To O
control O
the O
essence O
; O

To O
astringe O
the O
intestines B-PHE
and O
stop O
diarrhea B-PHE
; O

To O
decrease O
urination B-PHE

-DOCSTART- O


Treatment O
of O
edema B-PHE
with O
oliguria B-PHE
, O
dizziness B-PHE
and O
palpitation B-PHE
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-PHE
marked O
by O
anorexia B-PHE
, O
loose O
stools B-PHE
or O
diarrhea B-PHE
, O
restlessness B-PHE
and O
insomnia B-PHE
. O

-DOCSTART- O


disperse O
stasis B-PHE

-DOCSTART- O


clear O
( O
pathogenic O
) O
fire B-PHE
and O
invigorate O
blood B-PHE

-DOCSTART- O


Intravenous O
Anesthetic O
Interaction O
Unrecognized B-PHE
Condition I-PHE

-DOCSTART- O


Coronary B-PHE
heart I-PHE
disease I-PHE
, O
angina B-PHE
pectoris I-PHE
, O
hypercholesterolemia B-PHE
, O
Parkinson B-PHE
disease I-PHE
, O
peripheral B-PHE
arterial I-PHE
diseases I-PHE
, O
chest B-PHE
impediment I-PHE
and O
heart B-PHE
pain I-PHE
, O
cough B-PHE
of O
phlegm B-PHE
asthma B-PHE
, O
diarrhea B-PHE
and O
dysentery B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
emission B-PHE
, O
retinal B-PHE
insufficiency I-PHE
syndrome I-PHE
. O

-DOCSTART- O


nine O
kinds O
of O
illness B-PHE
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O


Endometriosis B-PHE

-DOCSTART- O


Treatment O
of O
scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
lower O
abdominal B-PHE
pain I-PHE
and O
cold B-PHE
sensation I-PHE
, O
distending B-PHE
pain I-PHE
in I-PHE
the I-PHE
epigastrium I-PHE
with O
anorexia B-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
, O
hydrocele B-PHE
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
caused O
by O
cold B-PHE
. O

-DOCSTART- O


Woman O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Small O
dosage O
of O
berberine O
enhances O
the O
action B-PHE
of I-PHE
acetylcholine I-PHE
on O
animals' O
hearts O
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O


To O
contract O
uterus O
and O
stanch O
bleeding O
, O
relieve O
pain O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
itching B-PHE
of O
the O
throat O
and O
profuse O
expectoration B-PHE
in I-PHE
colds I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
and O
epigastric B-PHE
distension I-PHE
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O


Hepatocellular B-PHE
Carcinoma I-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
with O
chest B-PHE
congested I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-PHE
, O
spleen B-PHE
and O
stomach B-PHE
, O
and O
to O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


Treatment O
of O
fever B-PHE
due O
to O
deficiency B-PHE
of O
yin O
, O
consumptive O
fever B-PHE
, O
fever B-PHE
in O
infantile O
malnutrition B-PHE
. O

-DOCSTART- O


The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic B-PHE
bile I-PHE
acids I-PHE
in O
the O
gastrointestinal B-PHE
tract I-PHE
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O


For O
the O
treatment O
of O
Tuberculosis B-PHE
and O
Tuberculosis-related O
mycobacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Breast B-PHE
Neoplasms I-PHE

-DOCSTART- O


a O
mass O
amount O
of O
phlegm B-PHE
, O
and O
dyspnea B-PHE
and O
cough B-PHE

-DOCSTART- O


damp B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthritis B-PHE
due O
to O
dampness B-PHE
; O
damp B-PHE
impediment O
[ O
blockage B-PHE
] O

-DOCSTART- O


distension B-PHE
and O
fullness B-PHE

-DOCSTART- O


To O
arrest O
discharges O
, O
promote O
healing O
of O
wounds B-PHE
and O
tissue B-PHE
regeneration I-PHE
, O
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-PHE
, O
bruises B-PHE
and O
arthritis B-PHE
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery I-PHE
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' B-PHE
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone B-PHE
injury I-PHE
and O
regulates O
bone B-PHE
metabolism I-PHE
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
spinal B-PHE
compression I-PHE
fracture I-PHE
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain O
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-PHE
began O
promptly O
after O
administration O
and O
the O
pain B-PHE
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-PHE
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-PHE
of O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
one O
spinal B-PHE
compression I-PHE
fracture I-PHE
. O

-DOCSTART- O


Treament O
of O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
amenorrhea B-PHE
with O
blood O
stasis O
, O
arthralgia B-PHE
, O
traumatic O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


1 O
To O
clear O
the O
lungs B-PHE
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-PHE
and O
promote O
the O
production B-PHE
of I-PHE
body I-PHE
fluids I-PHE

-DOCSTART- O


Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 O
receptors O
. O

Naproxen O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
enzymes I-PHE
cyclo-oxygenase I-PHE
I I-PHE
and I-PHE
II I-PHE
, O
resulting O
in O
a O
decreased O
formation B-PHE
of I-PHE
precursors I-PHE
of I-PHE
prostaglandins I-PHE
and I-PHE
thromboxanes I-PHE
. O

-DOCSTART- O


Melphalan O
alkylates O
DNA B-PHE
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA B-PHE
inter-strand I-PHE
cross-linkages I-PHE
, O
resulting O
in O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cytotoxicity B-PHE
against O
both O
dividing O
and O
non-dividing O
tumor B-PHE
cells I-PHE
. O

-DOCSTART- O


1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O
and O
NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


restrain O
acid B-PHE

-DOCSTART- O


warm O
the O
lumbus B-PHE
and O
knees B-PHE

-DOCSTART- O


night O
fever B-PHE
and O
chilling B-PHE
in O
the O
morning O

-DOCSTART- O


strengthen O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

GSK2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-PHE
of I-PHE
leukotrienes I-PHE
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ETE O
) O
. O

-DOCSTART- O


Others O

-DOCSTART- O


Quality O
of O
life O
, O
Others O

-DOCSTART- O


To O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-PHE
, O
disperse O
swelling B-PHE
toxin I-PHE
. O

-DOCSTART- O


Pneumonia B-PHE
, O
pyothorax B-PHE
, O
sore B-PHE
pharynx I-PHE
, O
oral B-PHE
ulcer I-PHE
, O
vesical B-PHE
calculus I-PHE
, O
swollen O
welling O
abscess B-PHE
. O

-DOCSTART- O


Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase B-PHE
II I-PHE
activity I-PHE
by O
stabilizing O
the O
DNA-topoisomerase B-PHE
II I-PHE
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase B-PHE
II I-PHE
catalyzes I-PHE
. O

-DOCSTART- O


Gout B-PHE

-DOCSTART- O


Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-PHE
, O
insomnia B-PHE
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-PHE
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor O
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor O
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors O
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor O
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor O
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O


Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-PHE
deficiency I-PHE
( O
TD B-PHE
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100 O
- O
500 O
microg O
/ O
ml O
) O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-PHE
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration O
- O
dependent O
manner O
. O

These O
substances O
inhibited O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-PHE
activity I-PHE
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O


Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O


warm O
the O
lung B-PHE

-DOCSTART- O


This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O


support O
five O
viscera B-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Atrophy B-PHE

-DOCSTART- O


Taxation B-PHE
damage I-PHE
and O
sinew B-PHE
bone I-PHE
pain I-PHE
, O
impotence B-PHE
, O
stomachache B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
knife B-PHE
wound I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Kids O
, O
Others O
, O
Fetus O

-DOCSTART- O


Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-PHE
artery I-PHE
significantly O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O


abdominal B-PHE
fullness I-PHE
; O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
nourish O
blood B-PHE

-DOCSTART- O


Its O
alcoholic O
extract O
inhibits O
the O
heart B-PHE
and O
lowers O
blood B-PHE
pressure I-PHE
in O
anesthetized O
cats O
. O

-DOCSTART- O


fever B-PHE
with O
dysphoria B-PHE
; O
dysphoria B-PHE
with O
smothery O
sensation O
; O
smothery O
fever B-PHE

-DOCSTART- O


ceruminal B-PHE
impaction I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
is O
lumped O
at O
the O
neck O

-DOCSTART- O


dizziness B-PHE

-DOCSTART- O


Organophosphate B-PHE
Poisoning I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
after O
phlegm B-PHE
due O
to O
Wind B-PHE
sidesae O
blocked O
Gi O
. O

-DOCSTART- O


Both O
acted O
at O
the O
same O
active O
site O
of O
penicillinbinding O
protein O
2A O
but O
at O
relatively O
high O
MICs O
of O
32 O
g/ml O
. O

The O
relatively O
high O
MICs O
make O
it O
less O
likely O
for O
both O
drugs O
to O
saturate O
target O
sites O
, O
thereby O
maintaining O
additive O
antibacterial B-PHE
effect I-PHE
. O

-DOCSTART- O


blood B-PHE
wind I-PHE
of O
female O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


Dim B-PHE
vision I-PHE
, O
flooding B-PHE
and O
spotting I-PHE
, O
bleeding I-PHE
due O
to O
external B-PHE
injury I-PHE
, O
sore B-PHE
toxin I-PHE
and O
intractable O
lichen B-PHE
. O

-DOCSTART- O


skin B-PHE
disease I-PHE
on O
palms O
. O

-DOCSTART- O


Ankylosing B-PHE
Spondylitis I-PHE

-DOCSTART- O


hoarseness B-PHE
due O
to O
singing O

-DOCSTART- O


dyspnea B-PHE
with O
coughing B-PHE

-DOCSTART- O


dry O
phlegm B-PHE
; O
dry-phlegm B-PHE
( O
syndrome O
) O

-DOCSTART- O


Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O


Water O
extract O
of O
Samultang O
reduces O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
h(2)o(2)-induced O
oxidative B-PHE
injury I-PHE
in O
sk-N-mc O
cells O
. O

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE
of O
the O
back O
; O

carbuncle B-PHE
on O
the O
back O

-DOCSTART- O


To O
eliminate O
fluid B-PHE
and O
relieve O
edema B-PHE
( O
sthenia-syndrome B-PHE
with O
edema B-PHE
and O
ascites B-PHE
) O
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE
; O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE

-DOCSTART- O


Wind-evil O
attacked O
meridian O
, O
facial B-PHE
paralysis I-PHE
, O
muscle B-PHE
numbness I-PHE
, O
pain B-PHE
of I-PHE
tendons I-PHE
and I-PHE
bone I-PHE
. O

-DOCSTART- O


For O
ascariasis B-PHE
and O
taeniasis B-PHE
. O

For O
constipation B-PHE
due O
to O
dryness B-PHE
of O
intestine O
. O

-DOCSTART- O


( O
1 O
) O
hematochezia B-PHE
( O
2 O
) O
viginal B-PHE
bleeding I-PHE

-DOCSTART- O


wind B-PHE
rash I-PHE
; O
German B-PHE
measles I-PHE
; O
rubella B-PHE
; O
urticaria B-PHE

-DOCSTART- O


traumatic B-PHE
cataract I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


eliminate O
vacuity O
and O
clod O
of O
the O
spleen O
and O
the O
stomach O

-DOCSTART- O


To O
dispel O
wind-damp B-PHE
, O
quicken O
blood B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Pregnancy B-PHE

-DOCSTART- O


To O
expel O
wind B-PHE
and O
heat B-PHE
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels O
. O

-DOCSTART- O


cool O
blood B-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Memory B-PHE

-DOCSTART- O


Hepatoma B-PHE

-DOCSTART- O


bloody B-PHE
stool I-PHE
; O
hematochezia B-PHE

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
stop O
pain B-PHE
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Perennial B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


Apical B-PHE
Ballooning I-PHE
Syndrome I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O
, O
Evacuation B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE
( O
OAB B-PHE
) O

-DOCSTART- O


For O
activating O
blood B-PHE
and O
modulating O
period O

-DOCSTART- O


To O
invigorate O
the O
function B-PHE
of I-PHE
the I-PHE
kidney I-PHE
, O
to O
alleviate O
asthma B-PHE
, O
and O
to O
relieve O
diarrhea B-PHE
. O

-DOCSTART- O


It O
may O
also O
bind O
to O
bacterial B-PHE
potassium I-PHE
transporters I-PHE
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O


Deficiency O
of O
yin O
of O
the O
liver B-PHE
and O
the O
kidney B-PHE
marked O
by O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
, O
dizziness B-PHE
and O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


sore B-PHE
of I-PHE
scrotum I-PHE

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

By O
binding O
to O
the O
ATP-binding O
site O
, O
enzastaurin O
selectively O
inhibits O
protein B-PHE
kinase I-PHE
C I-PHE
beta I-PHE
, O
which O
appears O
to O
be O
cytotoxic O
in O
cells O
with O
DNA B-PHE
alterations O
or O
DNA O
damage O
which O
may O
decrease O
tumor B-PHE
blood I-PHE
supply I-PHE
, O
preventing O
growth B-PHE
. O

-DOCSTART- O


RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-PHE
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O


deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-PHE

-DOCSTART- O


Schizophrenia B-PHE
Prodrome I-PHE

-DOCSTART- O


For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-PHE
associated O
with O
chronic B-PHE
renal I-PHE
failure I-PHE
( O
CRF B-PHE
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-PHE
and O
reduction B-PHE
of I-PHE
transfusion I-PHE
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-PHE
tumours I-PHE
, O
malignant B-PHE
lymphoma I-PHE
or O
multiple B-PHE
myeloma I-PHE
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia B-PHE
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-PHE
blood I-PHE
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Breast I-PHE

-DOCSTART- O


dissipate O
depression B-PHE

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE
due O
to O
visceral O
cold B-PHE

-DOCSTART- O


Motivation O
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Others O
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-PHE
circulation. I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE

-DOCSTART- O


epiphora B-PHE
; O
lacrimation B-PHE

-DOCSTART- O


Cardiovascular B-PHE
Disorder I-PHE

-DOCSTART- O


terminate O
delivery O

-DOCSTART- O


To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
promote O
eruption B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
resolve O
phlegm B-PHE
and O
benefit O
throat B-PHE

-DOCSTART- O


1 O
Aloperine O
inhibits O
exudative B-PHE
inflammation I-PHE
and O
hemolysis B-PHE
of O
red O
blood B-PHE
cells O
2 O
. O

Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-PHE
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O

3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 B-PHE
in O
vitro O
. O

-DOCSTART- O


Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-PHE
activities I-PHE
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-PHE
activity I-PHE
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-PHE
activity I-PHE
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity O
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


Decompensated B-PHE
Cirrhosis I-PHE

-DOCSTART- O


Cough B-PHE
and O
asthma B-PHE
, O
fright O
epilepsy B-PHE
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of I-PHE
rectum I-PHE
, O
knocks B-PHE
and O
falls B-PHE
. O

-DOCSTART- O


Cardiovascular B-PHE
Diseases I-PHE

-DOCSTART- O


1 O
Its O
decoction O
enhances O
th O
intestinal B-PHE
contraction I-PHE
and O
tensity O
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O

2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-PHE
180 I-PHE
in O
mice O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
, O
deprive O
dampness B-PHE
and O
kill O
parasites B-PHE
. O

For O
sorethroat B-PHE
, O
dysentery B-PHE
, O
trichomonas B-PHE
enteritis I-PHE
, O
toothache B-PHE
, O
stomachache B-PHE
and O
leucorrhagia B-PHE
, O
external O
use O
for O
tinea B-PHE
and O
eczema B-PHE
. O

2 O
To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
. O

3 O
Anticarcinogenic B-PHE
. O
For O
malignant B-PHE
hydatidiform I-PHE
mole I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
and O
leukemia B-PHE
. O

-DOCSTART- O


Knee B-PHE
Osteoarthritis I-PHE

-DOCSTART- O


Malignancy B-PHE

-DOCSTART- O


Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O


Crohn's B-PHE
Disease I-PHE

-DOCSTART- O


Swelling B-PHE
and O
pain B-PHE
due O
to O
blood B-PHE
stagnation I-PHE
caused O
by O
external B-PHE
injuries I-PHE
. O

-DOCSTART- O


Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
arthritis I-PHE
with O
muscular B-PHE
contracture I-PHE
, O
aching B-PHE
of O
the O
loins O
and O
knees O
, O
inflammation B-PHE
of O
the O
throat O
, O
carbuncle B-PHE
and O
boils O
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-PHE
of I-PHE
MTIC I-PHE
is O
due O
primarily O
to O
methylation B-PHE
of I-PHE
DNA I-PHE
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition B-PHE
of I-PHE
DNA I-PHE
replication I-PHE
. O

-DOCSTART- O


Growth B-PHE

-DOCSTART- O


Treatment O
of O
: O
1 O
Hemorrhages B-PHE
due O
to O
external B-PHE
injuries I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O


A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-PHE
pain I-PHE
and O
general O
fatigue B-PHE
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-PHE
pain I-PHE
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain B-PHE
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-PHE
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced B-PHE
pneumonitis I-PHE
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic B-PHE
pneumonitis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Alzheimer B-PHE
Disease I-PHE

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
subdue O
hyperactivity B-PHE
of I-PHE
the I-PHE
liver I-PHE
, O
and O
improve O
eyesight B-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
depression B-PHE
. O

-DOCSTART- O


To O
stop O
bleeding B-PHE
and O
promote O
the O
healing B-PHE
of I-PHE
wounds I-PHE
. O

-DOCSTART- O


seven O
injuries B-PHE
; O
seven O
kinds O
of O
impairments B-PHE

-DOCSTART- O


Regulation O
of O
qi O

-DOCSTART- O


Eye B-PHE
pain I-PHE
, O
eye B-PHE
swelling I-PHE
, O
red B-PHE
eyes I-PHE
and O
tearing B-PHE
. O

-DOCSTART- O


Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-PHE
coli I-PHE
. O

-DOCSTART- O


phthisical B-PHE
cough I-PHE
due O
to O
Eum O
deficiency O

-DOCSTART- O


swollen O
check O
, O
mumps B-PHE
; O
epidemic B-PHE
parotitis I-PHE

-DOCSTART- O


Infection B-PHE

-DOCSTART- O


Behavioral B-PHE
and I-PHE
psychological I-PHE
symptoms I-PHE
of I-PHE
dementia I-PHE
( O
BPSD B-PHE
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-PHE
disease I-PHE
( O
AD B-PHE
) O
and O
other O
forms O
of O
senile B-PHE
dementia I-PHE
. O

BPSD B-PHE
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-PHE
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-PHE
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-PHE
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-PHE
of I-PHE
the I-PHE
serotonin I-PHE
( O
5-HT B-PHE
) O
system O
such O
as O
5-HT2A O
receptors O
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-PHE
of O
AD B-PHE
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A O
receptors O
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced B-PHE
head-twitch I-PHE
response I-PHE
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch B-PHE
response I-PHE
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced B-PHE
head-twitch I-PHE
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-PHE
system I-PHE
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O


Obesity B-PHE

-DOCSTART- O


relieve O
pain B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
and O
relieve O
cough B-PHE
. O

For O
acute O
and O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Non-Small B-PHE
Cell I-PHE
Lung I-PHE
Cancer I-PHE

-DOCSTART- O


To O
regulate O
the O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of O
the O
ear O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


Retention B-PHE
of I-PHE
milk I-PHE
in O
babies O
, O
profuse O
sputum B-PHE
and O
infantile B-PHE
convulsions I-PHE
. O

-DOCSTART- O


To O
stablize O
liver B-PHE
and O
suppress O
dizziness B-PHE
; O
To O
soothe O
neck B-PHE
and O
wake-up O
brain B-PHE

-DOCSTART- O


burn B-PHE

-DOCSTART- O


Melanoma B-PHE

-DOCSTART- O


reddish B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
and O
nocturnal B-PHE
emission I-PHE

-DOCSTART- O


urinary B-PHE
incontinence I-PHE
; O
galacturia B-PHE
; O
stranguria B-PHE
with O
chyluria B-PHE
; O
stranguria B-PHE
marked O
by O
chyluria B-PHE

-DOCSTART- O


To O
dissipate O
stasis B-PHE
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


replenish O
essence-marrow O

-DOCSTART- O


( O
1 O
) O
diarrhea B-PHE
( O
2 O
) O
diarrhea B-PHE
and O
urination B-PHE
( O
3 O
) O
diarrhea B-PHE
and O
dysentery B-PHE

-DOCSTART- O


A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O


Ureteral B-PHE
Stent I-PHE
Occlusion I-PHE

-DOCSTART- O


De O
Novo O
Kidney O
Transplant O
Patients O

-DOCSTART- O


Glaucoma B-PHE

-DOCSTART- O


excessive O
drinking O
of O
water O
due O
to O
thirst B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews B-PHE
and O
free O
network O
vessels B-PHE
. O

-DOCSTART- O


Ovarian B-PHE
Hyperstimulation I-PHE
Syndrome I-PHE

-DOCSTART- O


Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-PHE
. O

-DOCSTART- O


moisten O
the O
liver B-PHE

-DOCSTART- O


vomiting B-PHE
of O
milk O

-DOCSTART- O


Oxcarbazepine O
produces O
blockade B-PHE
of I-PHE
voltage-sensitive I-PHE
sodium I-PHE
channels I-PHE
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-PHE
membranes I-PHE
, O
inhibition O
of O
repetitive B-PHE
neuronal I-PHE
firing I-PHE
, O
and O
diminution O
of O
propagation B-PHE
of I-PHE
synaptic I-PHE
impulses I-PHE
. O

These O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-PHE
spread I-PHE
in O
the O
intact O
brain O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated B-PHE
N-type I-PHE
calcium I-PHE
ion I-PHE
channels I-PHE
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-PHE
calcium I-PHE
channel I-PHE
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O


Toxoplasmosis B-PHE

-DOCSTART- O


white B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


nourish O
essence-marrow B-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


warm O
the O
menses B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
resolve O
phlegm B-PHE
and O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
obstruction B-PHE
in I-PHE
the I-PHE
channels I-PHE
. O

-DOCSTART- O


Atrophic B-PHE
Vaginitis I-PHE

-DOCSTART- O


Treatment O
of O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
with O
epigastric B-PHE
distension I-PHE
, O
diarrhea B-PHE
and O
abdominal B-PHE
pain I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
epigastric B-PHE
pain I-PHE
or O
abdominal B-PHE
colic I-PHE
, O
after O
childbirth O
, O
heraial O
pain B-PHE
, O
hyperlipemia B-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
dryness B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


profuse B-PHE
bleeding I-PHE
after O
delivery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Inv(16)(p13.1q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


secure O
the O
essence O

-DOCSTART- O


Septic B-PHE
Shock I-PHE

-DOCSTART- O


Sore B-PHE
Throat I-PHE
Due O
to O
a O
Common O
Cold B-PHE

-DOCSTART- O


Neuropathic B-PHE
pain I-PHE

-DOCSTART- O


cool O
blood B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


close O
sores B-PHE

-DOCSTART- O


Kids O
, O
Protective B-PHE
immunity I-PHE
, O
Metabolism B-PHE

-DOCSTART- O

Severe O
reversible O
left B-PHE
ventricular I-PHE
systolic I-PHE
and I-PHE
diastolic I-PHE
dysfunction I-PHE
due O
to O
accidental O
iatrogenic O
epinephrine O
overdose B-PHE
. O

Catecholamine-induced O
cardiomyopathy B-PHE
due O
to O
chronic O
excess O
of O
endogenous O
catecholamines O
has O
been O
recognized O
for O
decades O
as O
a O
clinical O
phenomenon O
. O

In O
contrast O
, O
reports O
of O
myocardial B-PHE
dysfunction I-PHE
due O
to O
acute O
iatrogenic O
overdose B-PHE
are O
rare O
. O

A O
35-year-old O
woman O
whose O
cervix O
uteri O
was O
inadvertently O
injected O
with O
8 O
mg O
of O
epinephrine O
developed O
myocardial B-PHE
stunning I-PHE
that O
was O
characterized O
by O
severe O
hemodynamic O
compromise O
, O
profound O
, O
albeit O
transient O
, O
left B-PHE
ventricular I-PHE
systolic I-PHE
and I-PHE
diastolic I-PHE
dysfunction I-PHE
, O
and O
only O
modestly O
elevated O
biochemical O
markers O
of O
myocardial B-PHE
necrosis I-PHE
. O

Our O
case O
illustrates O
the O
serious O
consequences O
of O
medical O
errors O
that O
can O
be O
avoided O
through O
improved O
medication O
labeling O
and O
staff O
supervision O
. O

-DOCSTART- O

Urinary B-PHE
bladder I-PHE
cancer I-PHE
in O
Wegener's B-PHE
granulomatosis I-PHE
: O
risks O
and O
relation O
to O
cyclophosphamide O
. O

OBJECTIVE O
: O
To O
assess O
and O
characterise O
the O
risk O
of O
bladder B-PHE
cancer I-PHE
, O
and O
its O
relation O
to O
cyclophosphamide O
, O
in O
patients O
with O
Wegener's B-PHE
granulomatosis I-PHE
. O

METHODS O
: O
In O
the O
population O
based O
, O
nationwide O
Swedish O
Inpatient O
Register O
a O
cohort O
of O
1065 O
patients O
with O
Wegener's B-PHE
granulomatosis I-PHE
, O
1969-95 O
, O
was O
identified O
. O

Through O
linkage O
with O
the O
Swedish O
Cancer B-PHE
Register O
, O
all O
subjects O
in O
this O
cohort O
diagnosed O
with O
bladder B-PHE
cancer I-PHE
were O
identified O
. O

Nested O
within O
the O
cohort O
, O
a O
matched O
case-control O
study O
was O
performed O
to O
estimate O
the O
association O
between O
cyclophosphamide O
and O
bladder B-PHE
cancer I-PHE
using O
odds O
ratios O
( O
ORs O
) O
as O
relative O
risk O
. O

In O
the O
cohort O
the O
cumulative O
risk O
of O
bladder B-PHE
cancer I-PHE
after O
Wegener's B-PHE
granulomatosis I-PHE
, O
and O
the O
relative O
prevalence O
of O
a O
history O
of O
bladder B-PHE
cancer I-PHE
at O
the O
time O
of O
diagnosis O
of O
Wegener's B-PHE
granulomatosis I-PHE
, O
were O
also O
estimated O
. O

RESULTS O
: O
The O
median O
cumulative O
doses O
of O
cyclophosphamide O
among O
cases O
(n O
= O
11 O
) O
and O
controls O
(n O
= O
25 O
) O
were O
113 O
g O
and O
25 O
g, O
respectively O
. O

The O
risk O
of O
bladder B-PHE
cancer I-PHE
doubled O
for O
every O
10 O
g O
increment O
in O
cyclophosphamide O
( O
OR O
= O
2.0 O
, O
95% O
confidence O
interval O
( O
CI O
) O
0.8 O
to O
4.9) O
. O

Treatment O
duration O
longer O
than O
1 O
year O
was O
associated O
with O
an O
eightfold O
increased O
risk O
( O
OR O
= O
7.7 O
, O
95% O
CI O
0.9 O
to O
69) O
. O

The O
absolute O
risk O
for O
bladder B-PHE
cancer I-PHE
in O
the O
cohort O
reached O
10% O
16 O
years O
after O
diagnosis O
of O
Wegener's B-PHE
granulomatosis I-PHE
, O
and O
a O
history O
of O
bladder B-PHE
cancer I-PHE
was O
( O
non-significantly O
) O
twice O
as O
common O
as O
expected O
at O
the O
time O
of O
diagnosis O
of O
Wegener's B-PHE
granulomatosis I-PHE
. O

CONCLUSION O
: O
The O
results O
indicate O
a O
dose-response O
relationship O
between O
cyclophosphamide O
and O
the O
risk O
of O
bladder B-PHE
cancer I-PHE
, O
high O
cumulative O
risks O
in O
the O
entire O
cohort O
, O
and O
also O
the O
possibility O
of O
risk O
factors O
operating O
even O
before O
Wegener's B-PHE
granulomatosis I-PHE
. O

-DOCSTART- O

L-arginine O
transport O
in O
humans O
with O
cortisol-induced O
hypertension B-PHE
. O

A O
deficient O
L-arginine-nitric O
oxide O
system O
is O
implicated O
in O
cortisol-induced O
hypertension B-PHE
. O

We O
investigate O
whether O
abnormalities O
in O
L-arginine O
uptake O
contribute O
to O
this O
deficiency O
. O

Eight O
healthy O
men O
were O
recruited O
. O

Hydrocortisone O
acetate O
( O
50 O
mg O
) O
was O
given O
orally O
every O
6 O
hours O
for O
24 O
hours O
after O
a O
5-day O
fixed-salt O
diet O
( O
150 O
mmol/d) O
. O

Crossover O
studies O
were O
performed O
2 O
weeks O
apart O
. O

Thirty O
milliliters O
of O
blood O
was O
obtained O
for O
isolation O
of O
peripheral O
blood O
mononuclear O
cells O
after O
each O
treatment O
period O
. O

L-arginine O
uptake O
was O
assessed O
in O
mononuclear O
cells O
incubated O
with O
L-arginine O
(1 O
to O
300 O
micromol/L) O
, O
incorporating O
100 O
nmol/L O
[3H]-l-arginine O
for O
a O
period O
of O
5 O
minutes O
at O
37 O
degrees O
C. O

Forearm O
[3H]-L-arginine O
extraction O
was O
calculated O
after O
infusion O
of O
[3H]-L-arginine O
into O
the O
brachial O
artery O
at O
a O
rate O
of O
100 O
nCi/min O
for O
80 O
minutes O
. O

Deep O
forearm O
venous O
samples O
were O
collected O
for O
determination O
of O
L-arginine O
extraction O
. O

Plasma O
cortisol O
concentrations O
were O
significantly O
raised O
during O
the O
active O
phase O
( O
323+/-43 O
to O
1082+/-245 O
mmol/L O
, O
P<0.05) O
. O

Systolic O
blood O
pressure O
was O
elevated O
by O
an O
average O
of O
7 O
mm O
Hg O
. O

Neither O
L-arginine O
transport O
into O
mononuclear O
cells O
( O
placebo O
vs O
active O
, O
26.3+/-3.6 O
vs O
29.0+/-2.1 O
pmol/10 O
000 O
cells O
per O
5 O
minutes O
, O
respectively O
, O
at O
an O
l-arginine O
concentration O
of O
300 O
micromol/L O
) O
nor O
L-arginine O
extraction O
in O
the O
forearm O
( O
at O
80 O
minutes O
, O
placebo O
vs O
active O
, O
1 O
868 O
904+/-434 O
962 O
vs O
2 O
013 O
910+/-770 O
619 O
disintegrations O
per O
minute O
) O
was O
affected O
by O
cortisol O
treatment O
; O
ie O
, O
that O
L-arginine O
uptake O
is O
not O
affected O
by O
short-term O
cortisol O
treatment O
. O

We O
conclude O
that O
cortisol-induced O
increases B-PHE
in I-PHE
blood I-PHE
pressure I-PHE
are O
not O
associated O
with O
abnormalities O
in O
the O
l-arginine O
transport O
system O
. O

-DOCSTART- O

MR O
imaging O
with O
quantitative O
diffusion O
mapping O
of O
tacrolimus-induced O
neurotoxicity B-PHE
in O
organ O
transplant O
patients O
. O

Our O
objective O
was O
to O
investigate O
brain O
MR O
imaging O
findings O
and O
the O
utility O
of O
diffusion-weighted O
( O
DW O
) O
imaging O
in O
organ O
transplant O
patients O
who O
developed O
neurologic O
symptoms O
during O
tacrolimus O
therapy O
. O

Brain O
MR O
studies O
, O
including O
DW O
imaging O
, O
were O
prospectively O
performed O
in O
14 O
organ O
transplant O
patients O
receiving O
tacrolimus O
who O
developed O
neurologic B-PHE
complications I-PHE
. O

In O
each O
patient O
who O
had O
abnormalities O
on O
the O
initial O
MR O
study O
, O
a O
follow-up O
MR O
study O
was O
performed O
1 O
month O
later O
. O

Apparent O
diffusion O
coefficient O
( O
ADC O
) O
values O
on O
the O
initial O
MR O
study O
were O
correlated O
with O
reversibility O
of O
the O
lesions O
. O

Of O
the O
14 O
patients O
, O
5 O
( O
35.7% O
) O
had O
white B-PHE
matter I-PHE
abnormalities I-PHE
, O
1 O
( O
7.1% O
) O
had O
putaminal B-PHE
hemorrhage I-PHE
, O
and O
8 O
( O
57.1% O
) O
had O
normal O
findings O
on O
initial O
MR O
images O
. O

Among O
the O
5 O
patients O
with O
white B-PHE
matter I-PHE
abnormalities I-PHE
, O
4 O
patients O
( O
80.0% O
) O
showed O
higher O
than O
normal O
ADC O
values O
on O
initial O
MR O
images O
, O
and O
all O
showed O
complete O
resolution O
on O
follow-up O
images O
. O

The O
remaining O
1 O
patient O
( O
20.0% O
) O
showed O
lower O
than O
normal O
ADC O
value O
and O
showed O
incomplete O
resolution O
with O
cortical B-PHE
laminar I-PHE
necrosis I-PHE
. O

Diffusion-weighted O
imaging O
may O
be O
useful O
in O
predicting O
the O
outcomes O
of O
the O
lesions O
of O
tacrolimus-induced O
neurotoxicity B-PHE
. O

-DOCSTART- O

Octreotide-induced O
hypoxemia B-PHE
and O
pulmonary B-PHE
hypertension I-PHE
in O
premature O
neonates O
. O

The O
authors O
report O
2 O
cases O
of O
premature O
neonates O
who O
had O
enterocutaneous O
fistula B-PHE
complicating O
necrotizing B-PHE
enterocolitis I-PHE
. O
Pulmonary B-PHE
hypertension I-PHE
developed O
after O
administration O
of O
a O
somatostatin O
analogue O
, O
octreotide O
, O
to O
enhance O
resolution O
of O
the O
fistula B-PHE
. O

The O
authors O
discuss O
the O
mechanism O
of O
the O
occurrence O
of O
this O
complication O
and O
recommend O
caution O
of O
its O
use O
in O
high-risk O
premature O
neonates O
. O

-DOCSTART- O

Sequential O
observations O
of O
exencephaly B-PHE
and O
subsequent O
morphological O
changes O
by O
mouse O
exo O
utero O
development O
system O
: O
analysis O
of O
the O
mechanism O
of O
transformation O
from O
exencephaly B-PHE
to O
anencephaly B-PHE
. O
Anencephaly B-PHE
has O
been O
suggested O
to O
develop O
from O
exencephaly B-PHE
; O
however O
, O
there O
is O
little O
direct O
experimental O
evidence O
to O
support O
this O
, O
and O
the O
mechanism O
of O
transformation O
remains O
unclear O
. O

We O
examined O
this O
theory O
using O
the O
exo O
utero O
development O
system O
that O
allows O
direct O
and O
sequential O
observations O
of O
mid- O
to O
late-gestation O
mouse O
embryos O
. O

We O
observed O
the O
exencephaly B-PHE
induced O
by O
5-azacytidine O
at O
embryonic O
day O
13.5 O
(E13.5) O
, O
let O
the O
embryos O
develop O
exo O
utero O
until O
E18.5 O
, O
and O
re-observed O
the O
same O
embryos O
at O
E18.5 O
. O

We O
confirmed O
several O
cases O
of O
transformation O
from O
exencephaly B-PHE
to O
anencephaly B-PHE
. O

However O
, O
in O
many O
cases O
, O
the O
exencephalic B-PHE
brain O
tissue O
was O
preserved O
with O
more O
or O
less O
reduction O
during O
this O
period O
. O

To O
analyze O
the O
transformation O
patterns O
, O
we O
classified O
the O
exencephaly B-PHE
by O
size O
and O
shape O
of O
the O
exencephalic B-PHE
tissue O
into O
several O
types O
at O
E13.5 O
and O
E18.5 O
. O

It O
was O
found O
that O
the O
transformation O
of O
exencephalic B-PHE
tissue O
was O
not O
simply O
size-dependent O
, O
and O
all O
cases O
of O
anencephaly B-PHE
at O
E18.5 O
resulted O
from O
embryos O
with O
a O
large O
amount O
of O
exencephalic B-PHE
tissue O
at O
E13.5 O
. O

Microscopic O
observation O
showed O
the O
configuration O
of O
exencephaly B-PHE
at O
E13.5 O
, O
frequent O
hemorrhaging B-PHE
and O
detachment O
of O
the O
neural O
plate O
from O
surface O
ectoderm O
in O
the O
exencephalic B-PHE
head O
at O
E15.5 O
, O
and O
multiple O
modes O
of O
reduction O
in O
the O
exencephalic B-PHE
tissue O
at O
E18.5 O
. O

From O
observations O
of O
the O
vasculature O
, O
altered O
distribution O
patterns O
of O
vessels O
were O
identified O
in O
the O
exencephalic B-PHE
head O
. O

These O
findings O
suggest O
that O
overgrowth O
of O
the O
exencephalic B-PHE
neural O
tissue O
causes O
the O
altered O
distribution O
patterns O
of O
vessels O
, O
subsequent O
peripheral O
circulatory B-PHE
failure I-PHE
and/or O
hemorrhaging B-PHE
in O
various O
parts O
of O
the O
exencephalic B-PHE
head O
, O
leading O
to O
the O
multiple O
modes O
of O
tissue O
reduction O
during O
transformation O
from O
exencephaly B-PHE
to O
anencephaly B-PHE
. O

-DOCSTART- O

Acute O
cocaine-induced O
seizures B-PHE
: O
differential O
sensitivity O
of O
six O
inbred O
mouse O
strains O
. O

Mature O
male O
and O
female O
mice O
from O
six O
inbred O
stains O
were O
tested O
for O
susceptibility O
to O
behavioral O
seizures B-PHE
induced O
by O
a O
single O
injection O
of O
cocaine O
. O

Cocaine O
was O
injected O
ip O
over O
a O
range O
of O
doses O
( O
50-100 O
mg/kg O
) O
and O
behavior O
was O
monitored O
for O
20 O
minutes O
. O
Seizure B-PHE
end O
points O
included O
latency O
to O
forelimb O
or O
hindlimb O
clonus O
, O
latency O
to O
clonic O
running O
seizure B-PHE
and O
latency O
to O
jumping O
bouncing O
seizure B-PHE
. O

A O
range O
of O
strain O
specific O
sensitivities O
was O
documented O
with O
A/J O
and O
SJL O
mice O
being O
most O
sensitive O
and O
C57BL/6J O
most O
resistant O
. O

DBA/2J O
, O
BALB/cByJ O
and O
NZW/LacJ O
strains O
exhibited O
intermediate O
sensitivity O
. O

EEG O
recordings O
were O
made O
in O
SJL O
, O
A/J O
and O
C57BL/6J O
mice O
revealing O
a O
close O
correspondence O
between O
electrical O
activity O
and O
behavior O
. O

Additionally O
, O
levels O
of O
cocaine O
determined O
in O
hippocampus O
and O
cortex O
were O
not O
different O
between O
sensitive O
and O
resistant O
strains O
. O

Additional O
studies O
of O
these O
murine O
strains O
may O
be O
useful O
for O
investigating O
genetic O
influences O
on O
cocaine-induced O
seizures B-PHE
. O

-DOCSTART- O

Microangiopathic B-PHE
hemolytic I-PHE
anemia I-PHE
complicating O
FK506 O
( O
tacrolimus O
) O
therapy O
. O

We O
describe O
3 O
episodes O
of O
microangiopathic B-PHE
hemolytic I-PHE
anemia I-PHE
( O
MAHA B-PHE
) O
in O
2 O
solid O
organ O
recipients O
under O
FK506 O
( O
tacrolimus O
) O
therapy O
. O

In O
both O
cases O
, O
discontinuation O
of O
FK506 O
and O
treatment O
with O
plasma O
exchange O
, O
fresh O
frozen O
plasma O
replacement O
, O
corticosteroids O
, O
aspirin O
, O
and O
dipyridamole O
led O
to O
resolution O
of O
MAHA B-PHE
. O

In O
one O
patient O
, O
reintroduction O
of O
FK506 O
led O
to O
rapid O
recurrence O
of O
MAHA B-PHE
. O

FK506-associated O
MAHA B-PHE
is O
probably O
rare O
but O
physicians O
must O
be O
aware O
of O
this O
severe O
complication O
. O

In O
our O
experience O
and O
according O
to O
the O
literature O
, O
FK506 O
does O
not O
seem O
to O
cross-react O
with O
cyclosporin O
A O
(CyA) O
, O
an O
immuno-suppressive O
drug O
already O
known O
to O
induce O
MAHA B-PHE
. O

-DOCSTART- O

Variant O
ventricular B-PHE
tachycardia I-PHE
in O
desipramine O
toxicity B-PHE
. O

We O
report O
a O
case O
of O
variant O
ventricular B-PHE
tachycardia I-PHE
induced O
by O
desipramine O
toxicity B-PHE
. O

Unusual O
features O
of O
the O
arrhythmia B-PHE
are O
repetitive O
group O
beating O
, O
progressive O
shortening O
of O
the O
R-R O
interval O
, O
progressive O
widening O
of O
the O
QRS O
complex O
with O
eventual O
failure O
of O
intraventricular O
conduction O
, O
and O
changes O
in O
direction O
of O
the O
QRS O
axis O
. O

Recognition O
of O
variant O
ventricular B-PHE
tachycardia I-PHE
is O
important O
because O
therapy O
differs O
from O
that O
of O
classic O
ventricular B-PHE
tachycardia I-PHE
. O

-DOCSTART- O

Desipramine-induced O
delirium B-PHE
at O
subtherapeutic O
concentrations O
: O
a O
case O
report O
. O

An O
elderly O
patient O
treated O
with O
low O
dose O
Desipramine O
developed O
a O
delirium B-PHE
while O
her O
plasma O
level O
was O
in O
the O
subtherapeutic O
range O
. O
Delirium B-PHE
, O
which O
may O
be O
induced O
by O
tricyclic O
drug O
therapy O
in O
the O
elderly O
, O
can O
be O
caused O
by O
tricyclics O
with O
low O
anticholinergic O
potency O
. O

Therapeutic O
ranges O
for O
antidepressants O
that O
have O
been O
derived O
from O
general O
adult O
population O
studies O
may O
not O
be O
appropriate O
for O
the O
elderly O
. O

Further O
studies O
of O
specifically O
elderly O
patients O
are O
now O
required O
to O
establish O
safer O
and O
more O
appropriate O
guidelines O
for O
drug O
therapy O
. O

-DOCSTART- O

Mouse O
strain-dependent O
effect O
of O
amantadine O
on O
motility O
and O
brain O
biogenic O
amines O
. O

The O
effect O
of O
amantadine O
hydrochloride O
, O
injected O
i.p O
. O
in O
6 O
increments O
of O
100 O
mg/kg O
each O
over O
30 O
hr O
, O
on O
mouse O
motility O
and O
whole O
brain O
content O
of O
selected O
biogenic O
amines O
and O
major O
metabolites O
was O
studied O
in O
4 O
strains O
of O
mice O
. O

These O
were O
the O
albino O
Sprague-Dawley O
ICR O
and O
BALB/C O
, O
the O
black O
C57BL/6 O
and O
the O
brown O
CDF-I O
mouse O
strains O
. O

Amantadine O
treatment O
produced O
a O
biphasic O
effect O
on O
mouse O
motility O
. O

The O
initial O
dose O
of O
amantadine O
depressed B-PHE
locomotor O
activity O
in O
all O
mouse O
strains O
studied O
with O
the O
BALB/C O
mice O
being O
the O
most O
sensitive O
. O

Subsequent O
amantadine O
treatments O
produced O
enhancement O
of O
motility O
from O
corresponding O
control O
in O
all O
mouse O
strains O
with O
the O
BALB/C O
mice O
being O
the O
least O
sensitive O
. O

The O
locomotor O
activity O
was O
decreased O
from O
corresponding O
controls O
in O
all O
strains O
studied O
, O
except O
for O
the O
ICR O
mice O
, O
during O
an O
overnight O
drug-free O
period O
following O
the O
fourth O
amantadine O
treatment O
. O

Readministration O
of O
amantadine O
, O
after O
a O
drug-free O
overnight O
period O
, O
increased O
motility O
from O
respective O
saline O
control O
in O
all O
strains O
with O
exception O
of O
the O
BALB/C O
mice O
where O
suppression B-PHE
of I-PHE
motility I-PHE
occurred O
. O

Treatment O
with O
amantadine O
did O
not O
alter O
whole O
brain O
dopamine O
levels O
but O
decreased O
the O
amounts O
of O
3,4-dihydroxyphenylacetic O
acid O
in O
the O
BALB/C O
mice O
compared O
to O
saline O
control O
. O

Conversely O
, O
brain O
normetanephrine O
concentration O
was O
increased O
from O
saline O
control O
by O
amantadine O
in O
the O
BALB/C O
mice O
. O

The O
results O
suggest O
a O
strain-dependent O
effect O
of O
amantadine O
on O
motility O
and O
indicate O
a O
differential O
response O
to O
the O
acute O
and O
multiple O
dose O
regimens O
used O
. O

The O
BALB/C O
mouse O
was O
the O
most O
sensitive O
strain O
and O
could O
serve O
as O
the O
strain O
of O
choice O
for O
evaluating O
the O
side O
effects O
of O
amantadine O
. O

The O
biochemical O
results O
of O
brain O
biogenic O
amines O
of O
BALB/C O
mouse O
strain O
suggest O
a O
probable O
decrease O
of O
catecholamine O
turnover O
rate O
and/or O
metabolism O
by O
monoamine O
oxidase O
and O
a O
resulting O
increase O
in O
O-methylation O
of O
norepinephrine O
which O
may O
account O
for O
a O
behavioral B-PHE
depression I-PHE
caused O
by O
amantadine O
in O
the O
BALB/C O
mice O
. O

-DOCSTART- O

No O
enhancement O
by O
phenobarbital O
of O
the O
hepatocarcinogenicity O
of O
a O
choline-devoid O
diet O
in O
the O
rat O
. O

An O
experiment O
was O
performed O
to O
test O
whether O
inclusion O
of O
phenobarbital O
in O
a O
choline-devoid O
diet O
would O
increase O
the O
hepatocarcinogenicity O
of O
the O
diet O
. O

Groups O
of O
5-week O
old O
male O
Fischer-344 O
rats O
were O
fed O
for O
7-25 O
months O
semipurified O
choline-devoid O
or O
choline-supplemented O
diets O
, O
containing O
or O
not O
0.06% O
phenobarbital O
. O

No O
hepatic O
preneoplastic O
nodules O
or O
hepatocellular B-PHE
carcinomas I-PHE
developed O
in O
rats O
fed O
the O
plain O
choline-supplemented O
diet O
, O
while O
one O
preneoplastic O
nodule O
and O
one O
hepatocellular B-PHE
carcinoma I-PHE
developed O
in O
two O
rats O
fed O
the O
same O
diet O
containing O
phenobarbital O
. O

The O
incidence O
of O
preneoplastic O
nodules O
and O
of O
hepatocellular B-PHE
carcinomas I-PHE
was O
10% O
and O
37% O
, O
respectively O
, O
in O
rats O
fed O
the O
plain O
choline-devoid O
diet O
, O
and O
17% O
and O
30% O
, O
in O
rats O
fed O
the O
phenobarbital-containing O
choline-devoid O
diet O
. O

The O
results O
evinced O
no O
enhancement O
of O
the O
hepatocarcinogenicity O
of O
the O
choline-devoid O
diet O
by O
phenobarbital O
. O

Sporadic O
neoplastic O
lesions O
were O
observed O
in O
organs O
other O
than O
the O
liver O
of O
some O
of O
the O
animals O
, O
irrespective O
of O
the O
diet O
fed O
. O

-DOCSTART- O

Effect O
of O
direct O
intracoronary O
administration O
of O
methylergonovine O
in O
patients O
with O
and O
without O
variant B-PHE
angina I-PHE
. O

The O
effects O
of O
intracoronary O
administration O
of O
methylergonovine O
were O
studied O
in O
21 O
patients O
with O
variant B-PHE
angina I-PHE
and O
22 O
patients O
with O
atypical O
chest B-PHE
pain I-PHE
and O
in O
others O
without O
angina B-PHE
pectoris I-PHE
( O
control O
group) O
. O

Methylergonovine O
was O
administered O
continuously O
at O
a O
rate O
of O
10 O
micrograms/min O
up O
to O
50 O
micrograms O
. O

In O
all O
patients O
with O
variant B-PHE
angina I-PHE
, O
coronary B-PHE
spasm I-PHE
was O
provoked O
at O
a O
mean O
dose O
of O
28 O
+/- O
13 O
micrograms O
( O
mean O
+/- O
SD) O
. O

In O
the O
control O
group O
neither O
ischemic O
ST O
change O
nor O
localized O
spasm B-PHE
occurred O
. O

The O
basal O
tone O
of O
the O
right O
coronary O
artery O
was O
significantly O
lower O
than O
that O
of O
the O
left O
coronary O
artery O
. O

The O
percentage O
of O
vasoconstriction O
of O
the O
right O
coronary O
artery O
was O
significantly O
higher O
than O
that O
of O
the O
left O
coronary O
artery O
. O

These O
results O
suggest O
that O
spasm B-PHE
provocation O
tests O
, O
which O
use O
an O
intracoronary O
injection O
of O
a O
relatively O
low O
dose O
of O
methylergonovine O
, O
have O
a O
high O
sensitivity O
in O
variant B-PHE
angina I-PHE
and O
the O
vasoreactivity O
of O
the O
right O
coronary O
artery O
may O
be O
greater O
than O
that O
of O
the O
other O
coronary O
arteries O
. O

-DOCSTART- O

Dobutamine O
stress O
echocardiography O
: O
a O
sensitive O
indicator O
of O
diminished O
myocardial O
function O
in O
asymptomatic O
doxorubicin-treated O
long-term O
survivors O
of O
childhood O
cancer B-PHE
. O

Doxorubicin O
is O
an O
effective O
anticancer O
chemotherapeutic O
agent O
known O
to O
cause O
acute O
and O
chronic O
cardiomyopathy B-PHE
. O

To O
develop O
a O
more O
sensitive O
echocardiographic O
screening O
test O
for O
cardiac B-PHE
damage I-PHE
due O
to O
doxorubicin O
, O
a O
cohort O
study O
was O
performed O
using O
dobutamine O
infusion O
to O
differentiate O
asymptomatic O
long-term O
survivors O
of O
childhood O
cancer B-PHE
treated O
with O
doxorubicin O
from O
healthy O
control O
subjects O
. O

Echocardiographic O
data O
from O
the O
experimental O
group O
of O
21 O
patients O
( O
mean O
age O
16 O
+/- O
5 O
years O
) O
treated O
from O
1.6 O
to O
14.3 O
years O
( O
median O
5.3 O
) O
before O
this O
study O
with O
27 O
to O
532 O
mg/m2 O
of O
doxorubicin O
( O
mean O
196 O
) O
were O
compared O
with O
echocardiographic O
data O
from O
12 O
normal O
age-matched O
control O
subjects O
. O

Graded O
dobutamine O
infusions O
of O
0.5 O
, O
2.5 O
, O
5 O
and O
10 O
micrograms/kg O
per O
min O
were O
administered O
. O

Echocardiographic O
Doppler O
studies O
were O
performed O
before O
infusion O
and O
after O
15 O
min O
of O
infusion O
at O
each O
rate O
. O

Dobutamine O
infusion O
at O
10 O
micrograms/kg O
per O
min O
was O
discontinued O
after O
six O
studies O
secondary O
to O
a O
50% O
incidence O
rate O
of O
adverse O
symptoms O
. O

The O
most O
important O
findings O
were O
that O
compared O
with O
values O
in O
control O
subjects O
, O
end-systolic O
left O
ventricular O
posterior O
wall O
dimension O
and O
percent O
of O
left O
ventricular O
posterior O
wall O
thickening O
in O
doxorubicin-treated O
patients O
were O
decreased O
at O
baseline O
study O
and O
these O
findings O
were O
more O
clearly O
delineated O
with O
dobutamine O
stimulation O
. O

End-systolic O
left O
ventricular O
posterior O
wall O
dimension O
at O
baseline O
for O
the O
doxorubicin-treated O
group O
was O
11 O
+/- O
1.9 O
mm O
versus O
13.1 O
+/- O
1.5 O
mm O
for O
control O
subjects O
(p O
less O
than O
0.01) O
. O

End-systolic O
left O
ventricular O
posterior O
wall O
dimension O
at O
the O
5-micrograms/kg O
per O
min O
dobutamine O
infusion O
for O
the O
doxorubicin-treated O
group O
was O
14.1 O
+/- O
2.4 O
mm O
versus O
19.3 O
+/- O
2.6 O
mm O
for O
control O
subjects O
(p O
less O
than O
0.01).(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

-DOCSTART- O

Effects O
of O
aminophylline O
on O
the O
threshold O
for O
initiating O
ventricular B-PHE
fibrillation I-PHE
during O
respiratory B-PHE
failure I-PHE
. O
Cardiac B-PHE
arrhythmias I-PHE
have O
frequently O
been O
reported O
in O
association O
with O
respiratory B-PHE
failure I-PHE
. O

The O
possible O
additive O
role O
of O
pharmacologic O
agents O
in O
precipitating O
cardiac B-PHE
disturbances I-PHE
in O
patients O
with O
respiratory B-PHE
failure I-PHE
has O
only O
recently O
been O
emphasized O
. O

The O
effects O
of O
aminophylline O
on O
the O
ventricular B-PHE
fibrillation I-PHE
threshold O
during O
normal O
acid-base O
conditions O
and O
during O
respiratory B-PHE
failure I-PHE
were O
studied O
in O
anesthetized O
open O
chest O
dogs O
. O

The O
ventricular B-PHE
fibrillation I-PHE
threshold O
was O
measured O
by O
passing O
a O
gated O
train O
of O
12 O
constant O
current O
pulses O
through O
the O
ventricular O
myocardium O
during O
the O
vulnerable O
period O
of O
the O
cardiac O
cycle O
. O

During O
the O
infusion O
of O
aminophylline O
, O
the O
ventricular B-PHE
fibrillation I-PHE
threshold O
was O
reduced O
by O
30 O
to O
40 O
percent O
of O
the O
control O
when O
pH O
and O
partial O
pressures O
of O
oxygen O
( O
PO2 O
) O
and O
carbon O
dioxide O
( O
CO2 O
) O
were O
kept O
within O
normal O
limits O
. O

When O
respiratory B-PHE
failure I-PHE
was O
produced O
by O
hypoventilation B-PHE
( O
pH O
7.05 O
to O
7.25 O
; O
PC02 O
70 O
to O
100 O
mm O
Hg O
: O
P02 O
20 O
to O
40 O
mm O
Hg) O
, O
infusion O
of O
aminophylline O
resulted O
in O
an O
even O
greater O
decrease O
in O
ventricular B-PHE
fibrillation I-PHE
threshold O
to O
60 O
percent O
of O
the O
control O
level O
. O

These O
experiments O
suggest O
that O
although O
many O
factors O
may O
contribute O
to O
the O
increased O
incidence O
of O
ventricular B-PHE
arrhythmias I-PHE
in O
respiratory B-PHE
failure I-PHE
, O
pharmacologic O
agents O
, O
particularly O
aminophylline O
, O
may O
play O
a O
significant O
role O
. O

-DOCSTART- O

Case O
report O
: O
acute O
unintentional O
carbachol O
intoxication O
. O

INTRODUCTION O
: O
Intoxications O
with O
carbachol O
, O
a O
muscarinic O
cholinergic O
receptor O
agonist O
are O
rare O
. O

We O
report O
an O
interesting O
case O
investigating O
a O
( O
near O
) O
fatal O
poisoning B-PHE
. O

METHODS O
: O
The O
son O
of O
an O
84-year-old O
male O
discovered O
a O
newspaper O
report O
stating O
clinical O
success O
with O
plant O
extracts O
in O
Alzheimer's B-PHE
disease I-PHE
. O

The O
mode O
of O
action O
was O
said O
to O
be O
comparable O
to O
that O
of O
the O
synthetic O
compound O
'carbamylcholin' O
; O
that O
is O
, O
carbachol O
. O

He O
bought O
25 O
g O
of O
carbachol O
as O
pure O
substance O
in O
a O
pharmacy O
, O
and O
the O
father O
was O
administered O
400 O
to O
500 O
mg O
. O

Carbachol O
concentrations O
in O
serum O
and O
urine O
on O
day O
1 O
and O
2 O
of O
hospital O
admission O
were O
analysed O
by O
HPLC-mass O
spectrometry O
. O

RESULTS O
: O
Minutes O
after O
oral O
administration O
, O
the O
patient O
developed O
nausea B-PHE
, O
sweating O
and O
hypotension B-PHE
, O
and O
finally O
collapsed O
. O
Bradycardia B-PHE
, O
cholinergic O
symptoms O
and O
asystole B-PHE
occurred O
. O

Initial O
cardiopulmonary O
resuscitation O
and O
immediate O
treatment O
with O
adrenaline O
(epinephrine) O
, O
atropine O
and O
furosemide O
was O
successful O
. O

On O
hospital O
admission O
, O
blood O
pressure O
of O
the O
intubated O
, O
bradyarrhythmic O
patient O
was O
100/65 O
mmHg O
. O

Further O
signs O
were O
hyperhidrosis B-PHE
, O
hypersalivation B-PHE
, O
bronchorrhoea B-PHE
, O
and O
severe O
miosis B-PHE
; O
the O
electrocardiographic O
finding O
was O
atrio-ventricular B-PHE
dissociation I-PHE
. O

High O
doses O
of O
atropine O
( O
up O
to O
50 O
mg O
per O
24 O
hours) O
, O
adrenaline O
and O
dopamine O
were O
necessary O
. O

The O
patient O
was O
extubated O
1 O
week O
later O
. O

However O
, O
increased O
dyspnoea B-PHE
and O
bronchospasm B-PHE
necessitated O
reintubation O
. O
Respiratory B-PHE
insufficiency I-PHE
was O
further O
worsened O
by O
Proteus B-PHE
mirabilis I-PHE
infection I-PHE
and O
severe O
bronchoconstriction O
. O

One O
week O
later O
, O
the O
patient O
was O
again O
extubated O
and O
3 O
days O
later O
was O
transferred O
to O
a O
peripheral O
ward O
. O

On O
the O
next O
day O
he O
died O
, O
probably O
as O
a O
result O
of O
heart B-PHE
failure I-PHE
. O

Serum O
samples O
from O
the O
first O
and O
second O
days O
contained O
3.6 O
and O
1.9 O
mg/l O
carbachol O
, O
respectively O
. O

The O
corresponding O
urine O
concentrations O
amounted O
to O
374 O
and O
554 O
mg/l O
. O

CONCLUSION O
: O
This O
case O
started O
with O
a O
media O
report O
in O
a O
popular O
newspaper O
, O
initiated O
by O
published O
, O
peer-reviewed O
research O
on O
herbals O
, O
and O
involved O
human O
failure O
in O
a O
case O
history O
, O
medical O
examination O
and O
clinical O
treatment O
. O

For O
the O
first O
time O
, O
an O
analytical O
method O
for O
the O
determination O
of O
carbachol O
in O
plasma O
and O
urine O
has O
been O
developed O
. O

The O
analysed O
carbachol O
concentration O
exceeded O
the O
supposed O
serum O
level O
resulting O
from O
a O
therapeutic O
dose O
by O
a O
factor O
of O
130 O
to O
260 O
. O

Especially O
in O
old O
patients O
, O
intensivists O
should O
consider O
intoxications O
( O
with O
cholinergics O
) O
as O
a O
cause O
of O
acute B-PHE
cardiovascular I-PHE
failure I-PHE
. O

-DOCSTART- O

Crossover O
comparison O
of O
efficacy O
and O
preference O
for O
rizatriptan O
10 O
mg O
versus O
ergotamine/caffeine O
in O
migraine B-PHE
. O

Rizatriptan O
is O
a O
selective O
5-HT(1B/1D O
) O
receptor O
agonist O
with O
rapid O
oral O
absorption O
and O
early O
onset O
of O
action O
in O
the O
acute O
treatment O
of O
migraine B-PHE
. O

This O
randomized O
double- O
blind O
crossover O
outpatient O
study O
assessed O
the O
preference O
for O
1 O
rizatriptan O
10 O
mg O
tablet O
to O
2 O
ergotamine O
1 O
mg/caffeine O
100 O
mg O
tablets O
in O
439 O
patients O
treating O
a O
single O
migraine B-PHE
attack O
with O
each O
therapy O
. O

Of O
patients O
expressing O
a O
preference O
(89.1%) O
, O
more O
than O
twice O
as O
many O
preferred O
rizatriptan O
to O
ergotamine/caffeine O
( O
69.9 O
vs O
. O
30.1% O
, O
p O
< O
or O
= O
0.001) O
. O

Faster O
relief O
of O
headache B-PHE
was O
the O
most O
important O
reason O
for O
preference O
, O
cited O
by O
67.3% O
of O
patients O
preferring O
rizatriptan O
and O
54.2% O
of O
patients O
who O
preferred O
ergotamine/caffeine O
. O

The O
co-primary O
endpoint O
of O
being O
pain B-PHE
free O
at O
2 O
h O
was O
also O
in O
favor O
of O
rizatriptan O
. O

Forty-nine O
percent O
of O
patients O
were O
pain B-PHE
free O
2 O
h O
after O
rizatriptan O
, O
compared O
with O
24.3% O
treated O
with O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001) O
, O
rizatriptan O
being O
superior O
within O
1 O
h O
of O
treatment O
. O
Headache B-PHE
relief O
at O
2 O
h O
was O
75.9% O
for O
rizatriptan O
and O
47.3% O
for O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001) O
, O
with O
rizatriptan O
being O
superior O
to O
ergotamine/caffeine O
within O
30 O
min O
of O
dosing O
. O

Almost O
36% O
of O
patients O
taking O
rizatriptan O
were O
pain B-PHE
free O
at O
2 O
h O
and O
had O
no O
recurrence O
or O
need O
for O
additional O
medication O
within O
24 O
h, O
compared O
to O
20% O
of O
patients O
on O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001) O
. O

Rizatriptan O
was O
also O
superior O
to O
ergotamine/caffeine O
in O
the O
proportions O
of O
patients O
with O
no O
nausea B-PHE
, O
vomiting B-PHE
, O
phonophobia B-PHE
or O
photophobia B-PHE
and O
for O
patients O
with O
normal O
function O
2 O
h O
after O
drug O
intake O
(p O
< O
or O
= O
0.001) O
. O

More O
patients O
were O
(completely O
, O
very O
or O
somewhat O
) O
satisfied O
2 O
h O
after O
treatment O
with O
rizatriptan O
( O
69.8% O
) O
than O
at O
2 O
h O
after O
treatment O
with O
ergotamine/caffeine O
(38.6% O
, O
p O
< O
or O
= O
0.001) O
. O

Recurrence O
rates O
were O
31.4% O
with O
rizatriptan O
and O
15.3% O
with O
ergotamine/caffeine O
. O

Both O
active O
treatments O
were O
well O
tolerated O
. O

The O
most O
common O
adverse O
events O
( O
incidence O
> O
or O
= O
5% O
in O
one O
group O
) O
after O
rizatriptan O
and O
ergotamine/caffeine O
, O
respectively O
, O
were O
dizziness B-PHE
( O
6.7 O
and O
5.3%) O
, O
nausea B-PHE
( O
4.2 O
and O
8.5% O
) O
and O
somnolence B-PHE
( O
5.5 O
and O
2.3%) O
. O

-DOCSTART- O

Thrombotic B-PHE
microangiopathy I-PHE
and O
renal B-PHE
failure I-PHE
associated O
with O
antineoplastic O
chemotherapy O
. O

Five O
patients O
with O
carcinoma B-PHE
developed O
thrombotic B-PHE
microangiopathy I-PHE
( O
characterized O
by O
renal B-PHE
insufficiency I-PHE
, O
microangiopathic B-PHE
hemolytic I-PHE
anemia I-PHE
, O
and O
usually O
thrombocytopenia B-PHE
) O
after O
treatment O
with O
cisplatin O
, O
bleomycin O
, O
and O
a O
vinca O
alkaloid O
. O

One O
patient O
had O
thrombotic B-PHE
thrombocytopenic I-PHE
purpura I-PHE
, O
three O
the O
hemolytic-uremic B-PHE
syndrome I-PHE
, O
and O
one O
an O
apparent O
forme O
fruste O
of O
one O
of O
these O
disorders O
. O

Histologic O
examination O
of O
the O
renal O
tissue O
showed O
evidence O
of O
intravascular B-PHE
coagulation I-PHE
, O
primarily O
affecting O
the O
small O
arteries O
, O
arterioles O
, O
and O
glomeruli O
. O

Because O
each O
patient O
was O
tumor B-PHE
-free O
or O
had O
only O
a O
small O
tumor B-PHE
at O
the O
onset O
of O
this O
syndrome O
, O
the O
thrombotic B-PHE
microangiopathy I-PHE
may O
have O
been O
induced O
by O
chemotherapy O
. O

Diagnosis O
of O
this O
potentially O
fatal O
complication O
may O
be O
delayed O
or O
missed O
if O
renal O
tissue O
or O
the O
peripheral O
blood O
smear O
is O
not O
examined O
, O
because O
renal B-PHE
failure I-PHE
may O
be O
ascribed O
to O
cisplatin O
nephrotoxicity B-PHE
and O
the O
anemia B-PHE
and O
thrombocytopenia B-PHE
to O
drug-induced O
bone B-PHE
marrow I-PHE
suppression I-PHE
. O

-DOCSTART- O

Salvage O
therapy O
with O
nelarabine O
, O
etoposide O
, O
and O
cyclophosphamide O
in O
relapsed/refractory O
paediatric O
T-cell B-PHE
lymphoblastic I-PHE
leukaemia I-PHE
and I-PHE
lymphoma I-PHE
. O

A O
combination O
of O
5 O
d O
of O
nelarabine O
( O
AraG O
) O
with O
5 O
d O
of O
etoposide O
( O
VP O
) O
and O
cyclophosphamide O
( O
CPM O
) O
and O
prophylactic O
intrathecal O
chemotherapy O
was O
used O
as O
salvage O
therapy O
in O
seven O
children O
with O
refractory O
or O
relapsed O
T-cell B-PHE
leukaemia I-PHE
or I-PHE
lymphoma I-PHE
. O

The O
most O
common O
side O
effects O
attributable O
to O
the O
AraG O
included O
Grade O
2 O
and O
3 O
sensory O
and O
motor O
neuropathy B-PHE
and O
musculoskeletal B-PHE
pain I-PHE
. O
Haematological B-PHE
toxicity I-PHE
was O
greater O
for O
the O
combination O
than O
AraG O
alone O
, O
although O
median O
time O
to O
neutrophil O
and O
platelet O
recovery O
was O
consistent O
with O
other O
salvage O
therapies O
. O

All O
patients O
had O
some O
response O
to O
the O
combined O
therapy O
and O
five O
of O
the O
seven O
went O
into O
complete O
remission O
after O
one O
or O
two O
courses O
of O
AraG/VP/CPM O
. O

Our O
experience O
supports O
the O
safety O
of O
giving O
AraG O
as O
salvage O
therapy O
in O
synchrony O
with O
etoposide O
and O
cyclophosphamide O
, O
although O
neurological B-PHE
toxicity I-PHE
must O
be O
closely O
monitored O
. O

-DOCSTART- O

The O
3-week O
sulphasalazine O
syndrome O
strikes O
again O
. O

A O
34-year-old O
lady O
developed O
a O
constellation O
of O
dermatitis B-PHE
, O
fever B-PHE
, O
lymphadenopathy B-PHE
and O
hepatitis B-PHE
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine O
for O
sero-negative O
rheumatoid B-PHE
arthritis I-PHE
. O

Cervical O
and O
inguinal O
lymph O
node O
biopsies O
showed O
the O
features O
of O
severe O
necrotising O
lymphadenitis B-PHE
, O
associated O
with O
erythrophagocytosis O
and O
prominent O
eosinophilic O
infiltrates O
, O
without O
viral O
inclusion O
bodies O
, O
suggestive O
of O
an O
adverse B-PHE
drug I-PHE
reaction I-PHE
.A O
week O
later O
, O
fulminant O
drug-induced B-PHE
hepatitis I-PHE
, O
associated O
with O
the O
presence O
of O
anti-nuclear O
autoantibodies O
( O
but O
not O
with O
other O
markers O
of O
autoimmunity B-PHE
), O
and O
accompanied O
by O
multi-organ B-PHE
failure I-PHE
and O
sepsis B-PHE
, O
supervened O
. O

She O
subsequently O
died O
some O
5 O
weeks O
after O
the O
commencement O
of O
her O
drug O
therapy.Post-mortem O
examination O
showed O
evidence O
of O
massive B-PHE
hepatocellular I-PHE
necrosis I-PHE
, O
acute O
hypersensitivity O
myocarditis B-PHE
, O
focal O
acute O
tubulo-interstitial O
nephritis B-PHE
and O
extensive O
bone B-PHE
marrow I-PHE
necrosis I-PHE
, O
with O
no O
evidence O
of O
malignancy B-PHE
. O

It O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
3-week O
sulphasalazine O
syndrome O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic O
reaction O
to O
sulphasalazine O
. O

-DOCSTART- O

Bupropion O
( O
Zyban O
) O
toxicity B-PHE
. O

Bupropion O
is O
a O
monocyclic O
antidepressant O
structurally O
related O
to O
amphetamine O
. O

Zyban O
, O
a O
sustained-release O
formulation O
of O
bupropion O
hydrochloride O
, O
was O
recently O
released O
in O
Ireland O
, O
as O
a O
smoking O
cessation O
aid O
. O

In O
the O
initial O
6 O
months O
since O
it's O
introduction O
, O
12 O
overdose B-PHE
cases O
have O
been O
reported O
to O
The O
National O
Poisons O
Information O
Centre O
. O

8 O
patients O
developed O
symptoms O
of O
toxicity B-PHE
. O

Common O
features O
included O
tachycardia B-PHE
, O
drowsiness O
, O
hallucinations B-PHE
and O
convulsions B-PHE
. O

Two O
patients O
developed O
severe O
cardiac B-PHE
arrhythmias I-PHE
, O
including O
one O
patient O
who O
was O
resuscitated O
following O
a O
cardiac B-PHE
arrest I-PHE
. O

All O
patients O
recovered O
without O
sequelae O
. O

We O
report O
a O
case O
of O
a O
31 O
year O
old O
female O
who O
required O
admission O
to O
the O
Intensive O
Care O
Unit O
for O
ventilation O
and O
full O
supportive O
therapy O
, O
following O
ingestion O
of O
13.5g O
bupropion O
. O

Recurrent O
seizures B-PHE
were O
treated O
with O
diazepam O
and O
broad O
complex O
tachycardia B-PHE
was O
successfully O
treated O
with O
adenosine O
. O

Zyban O
caused O
significant O
neurological B-PHE
and I-PHE
cardiovascular I-PHE
toxicity I-PHE
in O
overdose B-PHE
. O

The O
potential O
toxic O
effects O
should O
be O
considered O
when O
prescribing O
it O
as O
a O
smoking O
cessation O
aid O
. O

-DOCSTART- O

Survey O
of O
complications O
of O
indocyanine O
green O
angiography O
in O
Japan O
. O

PURPOSE O
: O
We O
evaluated O
the O
safety O
of O
indocyanine O
green O
for O
use O
in O
fundus O
angiography O
. O

METHODS O
: O
We O
sent O
a O
questionnaire O
concerning O
complications O
of O
indocyanine O
green O
to O
32 O
institutions O
in O
Japan O
, O
which O
were O
selected O
on O
the O
basis O
of O
the O
client O
list O
from O
the O
Topcon O
Company O
, O
which O
manufactures O
the O
indocyanine O
green O
fundus O
camera O
. O

RESULTS O
: O
Ophthalmologists O
at O
15 O
institutions O
responded O
, O
reporting O
a O
total O
of O
3,774 O
indocyanine O
green O
angiograms O
performed O
on O
2,820 O
patients O
between O
June O
1984 O
and O
September O
1992 O
. O

Before O
angiography O
, O
intradermal O
or O
intravenous O
indocyanine O
green O
testing O
, O
or O
both O
was O
performed O
at O
13 O
of O
15 O
institutions O
. O

For O
three O
patients O
, O
the O
decision O
was O
made O
not O
to O
proceed O
with O
angiography O
after O
positive O
preangiographic O
testing O
. O

The O
dosage O
of O
indocyanine O
green O
used O
for O
angiography O
varied O
from O
25 O
to O
75 O
mg O
, O
depending O
upon O
the O
institution O
. O

There O
were O
13 O
cases O
of O
adverse O
reactions O
(0.34%) O
, O
ten O
of O
which O
were O
mild O
reactions O
such O
as O
nausea B-PHE
, O
exanthema B-PHE
, O
urtication B-PHE
, O
itchiness B-PHE
, O
and O
urgency O
to O
defecate O
, O
and O
did O
not O
require O
treatment O
. O

Also O
recorded O
were O
one O
case O
of O
pain B-PHE
of O
the O
vein O
, O
which O
required O
treatment O
, O
and O
two O
cases O
of O
hypotension B-PHE
. O

The O
two O
hypotensive B-PHE
patients O
required O
treatment O
for O
shock B-PHE
. O

CONCLUSIONS O
: O
A O
comparison O
of O
frequency O
of O
adverse O
reactions O
to O
indocyanine O
green O
with O
the O
previously O
reported O
frequency O
of O
such O
reactions O
to O
fluorescein O
sodium O
indicated O
that O
indocyanine O
green O
is O
a O
safe O
as O
fluorescein O
for O
use O
in O
angiography O
. O

-DOCSTART- O

Bradykinin O
receptors O
antagonists O
and O
nitric O
oxide O
synthase O
inhibitors O
in O
vincristine O
and O
streptozotocin O
induced O
hyperalgesia B-PHE
in O
chemotherapy O
and O
diabetic B-PHE
neuropathy I-PHE
rat O
model O
. O

PURPOSE O
: O
The O
influence O
of O
an O
irreversible O
inhibitor O
of O
constitutive O
NO O
synthase O
(L-NOArg O
; O
1.0 O
mg/kg O
ip) O
, O
a O
relatively O
selective O
inhibitor O
of O
inducible O
NO O
synthase O
(L-NIL O
; O
1.0 O
mg/kg O
ip O
) O
and O
a O
relatively O
specific O
inhibitor O
of O
neuronal O
NO O
synthase O
(7-NI O
; O
0.1 O
mg/kg O
ip) O
, O
on O
antihyperalgesic O
action O
of O
selective O
antagonists O
of O
B2 O
and O
B1 O
receptors O
: O
D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] O
bradykinin O
( O
HOE O
140 O
; O
70 O
nmol/kg O
ip O
) O
or O
des O
Arg10 O
HOE O
140 O
( O
70 O
nmol/kg O
ip O
) O
respectively O
, O
in O
model O
of O
diabetic B-PHE
( O
streptozotocin-induced I-PHE
) O
and I-PHE
toxic I-PHE
( O
vincristine-induced I-PHE
) O
neuropathy I-PHE
was O
investigated O
. O

METHODS O
: O
The O
changes O
in O
pain B-PHE
thresholds O
were O
determined O
using O
mechanical O
stimuli--the O
modification O
of O
the O
classic O
paw O
withdrawal O
test O
described O
by O
Randall-Selitto O
. O

RESULTS O
: O
The O
results O
of O
this O
paper O
confirm O
that O
inhibition O
of O
bradykinin O
receptors O
and O
inducible O
NO O
synthase O
but O
not O
neuronal O
NO O
synthase O
activity O
reduces O
diabetic B-PHE
hyperalgesia I-PHE
. O

Pretreatment O
with O
L-NOArg O
and O
L-NIL O
but O
not O
7-NI O
, O
significantly O
increases O
antihyperalgesic O
activity O
both O
HOE O
140 O
and O
des O
Arg10 O
HOE O
140 O
. O

It O
was O
also O
shown O
that O
both O
products O
of O
inducible O
NO O
synthase O
and O
neuronal O
NO O
synthase O
activation O
as O
well O
as O
bradykinin O
are O
involved O
in O
hyperalgesia B-PHE
produced O
by O
vincristine O
. O

Moreover O
, O
L-NOArg O
and O
7-NI O
but O
not O
L-NIL O
intensify O
antihyperalgesic O
activity O
of O
HOE O
140 O
or O
des-Arg10HOE O
140 O
in O
toxic B-PHE
neuropathy I-PHE
. O

CONCLUSIONS O
: O
Results O
of O
these O
studies O
suggest O
that O
B1 O
and O
B2 O
receptors O
are O
engaged O
in O
transmission O
of O
nociceptive O
stimuli O
in O
both O
diabetic B-PHE
and I-PHE
toxic I-PHE
neuropathy I-PHE
. O

In O
streptozotocin-induced O
hyperalgesia B-PHE
, O
inducible O
NO O
synthase O
participates O
in O
pronociceptive O
activity O
of O
bradykinin O
, O
whereas O
in O
vincristine-induced O
hyperalgesia B-PHE
bradykinin O
seemed O
to O
activate O
neuronal O
NO O
synthase O
pathway O
. O

Therefore O
, O
concomitant O
administration O
of O
small O
doses O
of O
bradykinin O
receptor O
antagonists O
and O
NO O
synthase O
inhibitors O
can O
be O
effective O
in O
alleviation O
of O
neuropathic B-PHE
pain I-PHE
, O
even O
in O
hospital O
care O
. O

-DOCSTART- O

Cardiac B-PHE
toxicity I-PHE
observed O
in O
association O
with O
high-dose O
cyclophosphamide-based O
chemotherapy O
for O
metastatic O
breast B-PHE
cancer I-PHE
. O

INTRODUCTION O
: O
Cyclophosphamide O
is O
an O
alkylating O
agent O
given O
frequently O
as O
a O
component O
of O
many O
conditioning O
regimens O
. O

In O
high O
doses O
, O
its O
nonhematological O
dose-limiting O
toxicity B-PHE
is O
cardiomyopathy B-PHE
. O

STUDY O
DESIGN O
: O
We O
combined O
paclitaxel O
, O
melphalan O
and O
high-dose O
cyclophosphamide O
, O
thiotepa O
, O
and O
carboplatin O
in O
a O
triple O
sequential O
high-dose O
regimen O
for O
patients O
with O
metastatic O
breast B-PHE
cancer I-PHE
. O

Analysis O
was O
performed O
on O
61 O
women O
with O
chemotherapy-responsive O
metastatic O
breast B-PHE
cancer I-PHE
receiving O
96-h O
infusional O
cyclophosphamide O
as O
part O
of O
a O
triple O
sequential O
high-dose O
regimen O
to O
assess O
association O
between O
presence O
of O
peritransplant O
congestive B-PHE
heart I-PHE
failure I-PHE
( O
CHF B-PHE
) O
and O
the O
following O
pretreatment O
characteristics O
: O
presence O
of O
electrocardiogram O
( O
EKG O
) O
abnormalities O
, O
age O
, O
hypertension B-PHE
, O
prior O
cardiac O
history O
, O
smoking O
, O
diabetes B-PHE
mellitus I-PHE
, O
prior O
use O
of O
anthracyclines O
, O
and O
left-sided O
chest O
irradiation O
. O

RESULTS O
: O
Six O
of O
61 O
women O
( O
10% O
) O
developed O
clinically O
reversible O
grade O
3 O
CHF B-PHE
following O
infusional O
cyclophosphamide O
with O
a O
median O
percent O
decline O
in O
ejection O
fraction O
of O
31% O
. O

Incidence O
of O
transient O
cyclophosphamide-related O
cardiac B-PHE
toxicity I-PHE
( O
10% O
) O
is O
comparable O
to O
previous O
recorded O
literature O
. O

Older O
age O
was O
significantly O
correlated O
with O
the O
CHF B-PHE
development O
; O
with O
median O
ages O
for O
the O
entire O
group O
and O
for O
patients O
developing O
CHF B-PHE
of O
45 O
and O
59 O
, O
respectively O
. O

No O
association O
was O
found O
with O
other O
pretreatment O
characteristics O
. O

CONCLUSIONS O
: O
As O
a O
result O
of O
these O
findings O
, O
oncologists O
should O
carefully O
monitor O
fluid O
balance O
in O
older O
patients O
. O

Routine O
EKG O
monitoring O
during O
infusional O
cyclophosphamide O
did O
not O
predict O
CHF B-PHE
development O
. O

-DOCSTART- O

Inappropriate O
use O
of O
carbamazepine O
and O
vigabatrin O
in O
typical O
absence B-PHE
seizures I-PHE
. O

Carbamazepine O
and O
vigabatrin O
are O
contraindicated O
in O
typical O
absence B-PHE
seizures I-PHE
. O

Of O
18 O
consecutive O
referrals O
of O
children O
with O
resistant O
typical O
absences O
only O
, O
eight O
were O
erroneously O
treated O
with O
carbamazepine O
either O
as O
monotherapy O
or O
as O
an O
add-on O
. O

Vigabatrin O
was O
also O
used O
in O
the O
treatment O
of O
two O
children O
. O

Frequency O
of O
absences O
increased O
in O
four O
children O
treated O
with O
carbamazepine O
and O
two O
of O
these O
developed O
myoclonic B-PHE
jerks I-PHE
, O
which O
resolved O
on O
withdrawal O
of O
carbamazepine O
. O

Absences O
were O
aggravated O
in O
both O
cases O
where O
vigabatrin O
was O
added O
on O
to O
concurrent O
treatment O
. O

Optimal O
control O
of O
the O
absences O
was O
achieved O
with O
sodium O
valproate O
, O
lamotrigine O
, O
or O
ethosuximide O
alone O
or O
in O
combination O
. O

-DOCSTART- O

Hemolytic B-PHE
anemia I-PHE
associated O
with O
the O
use O
of O
omeprazole O
. O

Omeprazole O
is O
the O
first O
drug O
designed O
to O
block O
the O
final O
step O
in O
the O
acid O
secretory O
process O
within O
the O
parietal O
cell O
. O

It O
has O
been O
shown O
to O
be O
extremely O
effective O
in O
the O
treatment O
of O
peptic B-PHE
ulcer I-PHE
disease I-PHE
, O
reflux B-PHE
esophagitis I-PHE
, O
and O
the O
Zollinger-Ellison B-PHE
syndrome I-PHE
. O

Although O
clinical O
experience O
with O
omeprazole O
is O
still O
limited O
, O
many O
controlled O
studies O
have O
established O
the O
short-term O
safety O
of O
this O
drug O
. O

We O
report O
the O
first O
case O
of O
a O
serious O
short-term O
adverse O
reaction O
with O
the O
use O
of O
omeprazole O
: O
hemolytic B-PHE
anemia I-PHE
. O

The O
patient O
developed O
weakness O
, O
lethargy B-PHE
, O
and O
shortness B-PHE
of I-PHE
breath I-PHE
2 O
days O
after O
starting O
therapy O
with O
omeprazole O
. O

Two O
weeks O
after O
the O
initiation O
of O
therapy O
, O
her O
hematocrit O
had O
decreased O
from O
44.1% O
to O
20.4% O
, O
and O
she O
had O
a O
positive O
direct O
Coombs O
antiglobulin O
test O
and O
an O
elevated O
indirect O
bilirubin O
. O

After O
she O
discontinued O
the O
omeprazole O
, O
her O
hemoglobin O
and O
hematocrit O
gradually O
returned O
to O
normal O
. O

The O
mechanism O
by O
which O
omeprazole O
caused O
the O
patient's O
hemolytic B-PHE
anemia I-PHE
is O
uncertain O
, O
but O
physicians O
should O
be O
alerted O
to O
this O
possible O
adverse O
effect O
. O

-DOCSTART- O

The O
use O
and O
toxicity B-PHE
of O
didanosine O
( O
ddI O
) O
in O
HIV B-PHE
antibody-positive I-PHE
individuals O
intolerant O
to O
zidovudine O
( O
AZT O
) O
One O
hundred O
and O
fifty-one O
patients O
intolerant O
to O
zidovudine O
( O
AZT O
) O
received O
didanosine O
( O
ddI O
) O
to O
a O
maximum O
dose O
of O
12.5 O
mg/kg/day O
. O

Patient O
response O
was O
assessed O
using O
changes O
in O
CD4+ O
lymphocyte O
subset O
count O
, O
HIV O
p24 O
antigen O
, O
weight O
, O
and O
quality O
of O
life O
. O

Seventy O
patients O
developed O
major O
opportunistic B-PHE
infections I-PHE
whilst O
on O
therapy O
; O
this O
was O
the O
first O
AIDS B-PHE
diagnosis O
in O
17 O
. O

Only O
minor O
changes O
in O
CD4+ O
lymphocyte O
subset O
count O
were O
observed O
in O
AIDS B-PHE
patients O
, O
although O
a O
more O
significant O
rise O
occurred O
in O
those O
with O
earlier O
stages O
of O
disease O
. O

Of O
those O
positive O
for O
p24 O
antigen O
at O
the O
commencement O
of O
the O
study O
67% O
showed O
a O
positive O
response O
, O
and O
this O
was O
most O
likely O
in O
those O
with O
CD4+ O
lymphocyte O
subset O
counts O
above O
100 O
mm3 O
. O

A O
positive O
weight O
response O
was O
seen O
in O
16% O
of O
patients O
. O

Most O
patients O
showed O
improvement O
in O
individual O
parameters O
and O
global O
score O
of O
quality O
of O
life O
. O

Adverse O
reactions O
possibly O
attributable O
to O
didanosine O
were O
common O
. O

The O
most O
common O
side-effect O
was O
diarrhoea B-PHE
, O
which O
resulted O
in O
cessation O
of O
therapy O
in O
19 O
individuals O
. O
Peripheral B-PHE
neuropathy I-PHE
occurred O
in O
12 O
patients O
and O
pancreatitis B-PHE
in O
six O
. O

Thirteen O
patients O
developed O
a O
raised O
serum O
amylase O
without O
abdominal B-PHE
pain I-PHE
. O

Seven O
patients O
developed O
glucose B-PHE
tolerance I-PHE
curves I-PHE
characteristic O
of O
diabetes B-PHE
but O
these O
were O
mild O
, O
did O
not O
require O
treatment O
and O
returned O
to O
normal O
on O
ceasing O
didanosine O
. O

-DOCSTART- O

Can O
angiogenesis O
be O
a O
target O
of O
treatment O
for O
ribavirin O
associated O
hemolytic B-PHE
anemia I-PHE
? O

BACKGROUND/AIMS O
: O
Recently O
ribavirin O
has O
been O
found O
to O
inhibit O
angiogenesis O
and O
a O
number O
of O
angiogenesis O
inhibitors O
such O
as O
sunitinib O
and O
sorafenib O
have O
been O
found O
to O
cause O
acute O
hemolysis B-PHE
. O

We O
aimed O
to O
investigate O
whether O
there O
is O
a O
relation O
between O
hemoglobin O
, O
haptoglobin O
and O
angiogenesis O
soluble O
markers O
which O
are O
modifiable O
and O
can O
help O
in O
developing O
strategies O
against O
anemia B-PHE
. O

METHODS O
: O
Fourteen O
patients O
chronically B-PHE
infected I-PHE
with I-PHE
hepatitis I-PHE
C I-PHE
virus I-PHE
were O
treated O
by O
pegylated O
interferon O
alpha O
2a O
and O
ribavirin O
. O

Serum O
hemoglobin O
, O
haptoglobin O
and O
angiogenesis O
markers O
of O
vascular O
endothelial O
growth O
factor O
and O
angiopoetin-2 O
were O
investigated O
before O
and O
after O
therapy O
. O

RESULTS O
: O
We O
observed O
a O
significant O
decrease O
in O
haptoglobin O
levels O
at O
the O
end O
of O
the O
treatment O
period O
. O

Hemoglobin O
levels O
also O
decreased O
but O
insignificantly O
by O
treatment O
. O

In O
contrast O
with O
the O
literature O
, O
serum O
levels O
of O
angiogenesis O
factors O
did O
not O
change O
significantly O
by O
pegylated O
interferon O
and O
ribavirin O
therapy O
. O

We O
found O
no O
correlation O
of O
angiogenesis O
soluble O
markers O
with O
either O
hemoglobin O
or O
haptoglobin O
. O

CONCLUSION O
: O
This O
is O
the O
first O
study O
in O
the O
literature O
investigating O
a O
link O
between O
angiogenesis O
soluble O
markers O
and O
ribavirin O
induced O
anemia B-PHE
in O
patients O
with O
hepatitis B-PHE
C I-PHE
and O
we O
could O
not O
find O
any O
relation O
. O

Future O
research O
with O
larger O
number O
of O
patients O
is O
needed O
to O
find O
out O
modifiable O
factors O
that O
will O
improve O
the O
safety O
of O
ribavirin O
therapy O
. O

-DOCSTART- O

Cocaine O
causes O
memory B-PHE
and I-PHE
learning I-PHE
impairments I-PHE
in O
rats O
: O
involvement O
of O
nuclear O
factor O
kappa O
B O
and O
oxidative O
stress O
, O
and O
prevention O
by O
topiramate O
. O

Different O
mechanisms O
have O
been O
suggested O
for O
cocaine O
toxicity B-PHE
including O
an O
increase O
in O
oxidative O
stress O
but O
the O
association O
between O
oxidative O
status O
in O
the O
brain O
and O
cocaine O
induced-behaviour O
is O
poorly O
understood O
. O

Nuclear O
factor O
kappa O
B O
( O
NFkappaB O
) O
is O
a O
sensor O
of O
oxidative O
stress O
and O
participates O
in O
memory O
formation O
that O
could O
be O
involved O
in O
drug O
toxicity B-PHE
and O
addiction O
mechanisms O
. O

Therefore O
NFkappaB O
activity O
, O
oxidative O
stress O
, O
neuronal O
nitric O
oxide O
synthase O
( O
nNOS O
) O
activity O
, O
spatial O
learning O
and O
memory O
as O
well O
as O
the O
effect O
of O
topiramate O
, O
a O
previously O
proposed O
therapy O
for O
cocaine B-PHE
addiction I-PHE
, O
were O
evaluated O
in O
an O
experimental O
model O
of O
cocaine O
administration O
in O
rats O
. O

NFkappaB O
activity O
was O
decreased O
in O
the O
frontal O
cortex O
of O
cocaine O
treated O
rats O
, O
as O
well O
as O
GSH O
concentration O
and O
glutathione O
peroxidase O
activity O
in O
the O
hippocampus O
, O
whereas O
nNOS O
activity O
in O
the O
hippocampus O
was O
increased O
. O

Memory O
retrieval O
of O
experiences O
acquired O
prior O
to O
cocaine O
administration O
was O
impaired O
and O
negatively O
correlated O
with O
NFkappaB O
activity O
in O
the O
frontal O
cortex O
. O

In O
contrast O
, O
learning O
of O
new O
tasks O
was O
enhanced O
and O
correlated O
with O
the O
increase O
of O
nNOS O
activity O
and O
the O
decrease O
of O
glutathione O
peroxidase O
. O

These O
results O
provide O
evidence O
for O
a O
possible O
mechanistic O
role O
of O
oxidative O
and O
nitrosative O
stress O
and O
NFkappaB O
in O
the O
alterations O
induced O
by O
cocaine O
. O

Topiramate O
prevented O
all O
the O
alterations O
observed O
, O
showing O
novel O
neuroprotective O
properties O
. O

-DOCSTART- O

Antinociceptive O
and O
antiamnesic O
properties O
of O
the O
presynaptic O
cholinergic O
amplifier O
PG-9 O
. O

The O
antinociceptive O
effect O
of O
3 O
alpha-tropyl O
2-(p-bromophenyl)propionate O
[(+/-)-PG-9] O
( O
10-40 O
mg O
kg-1 O
s.c. O
; O
30-60 O
mg O
kg-1 O
p.o. O
; O
10-30 O
mg O
kg-1 O
i.v. O
; O
10-30 O
micrograms/mouse O
i.c.v. O
) O
was O
examined O
in O
mice O
, O
rats O
and O
guinea O
pigs O
by O
use O
of O
the O
hot-plate O
, O
abdominal-constriction O
, O
tail-flick O
and O
paw-pressure O
tests O
. O

( O
+/-)-PG-9 O
antinociception O
peaked O
15 O
min O
after O
injection O
and O
then O
slowly O
diminished O
. O

The O
antinociception O
produced O
by O
( O
+/-)-PG-9 O
was O
prevented O
by O
the O
unselective O
muscarinic O
antagonist O
atropine O
, O
the O
M1-selective O
antagonists O
pirenzepine O
and O
dicyclomine O
and O
the O
acetylcholine O
depletor O
hemicholinium-3 O
, O
but O
not O
by O
the O
opioid O
antagonist O
naloxone O
, O
the O
gamma-aminobutyric O
acidB O
antagonist O
3-aminopropyl-diethoxy-methyl-phosphinic O
acid O
, O
the O
H3 O
agonist O
R-(alpha)-methylhistamine O
, O
the O
D2 O
antagonist O
quinpirole O
, O
the O
5-hydroxytryptamine4 O
antagonist O
2-methoxy-4-amino-5-chlorobenzoic O
acid O
2-(diethylamino)ethyl O
ester O
hydrochloride O
, O
the O
5-hydroxytryptamin1A O
antagonist O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine O
hydrobromide O
and O
the O
polyamines O
depletor O
reserpine O
. O

Based O
on O
these O
data O
, O
it O
can O
be O
postulated O
that O
( O
+/-)-PG-9 O
exerted O
an O
antinociceptive O
effect O
mediated O
by O
a O
central O
potentiation O
of O
cholinergic O
transmission O
. O

( O
+/-)-PG-9 O
( O
10-40 O
mg O
kg-1 O
i.p. O
) O
was O
able O
to O
prevent O
amnesia B-PHE
induced O
by O
scopolamine O
(1 O
mg O
kg-1 O
i.p. O
) O
and O
dicyclomine O
(2 O
mg O
kg-1 O
i.p. O
) O
in O
the O
mouse O
passive-avoidance O
test O
. O

Affinity O
profiles O
of O
( O
+/-)-PG-9 O
for O
muscarinic O
receptor O
subtypes O
, O
determined O
by O
functional O
studies O
( O
rabbit O
vas O
deferens O
for O
M1 O
, O
guinea O
pig O
atrium O
for O
M2 O
, O
guinea O
pig O
ileum O
for O
M3 O
and O
immature O
guinea O
pig O
uterus O
for O
putative O
M4) O
, O
have O
shown O
an O
M4/M1 O
selectivity O
ratio O
of O
10.2 O
that O
might O
be O
responsible O
for O
the O
antinociception O
and O
the O
anti- O
amnesic B-PHE
effect O
induced O
by O
( O
+/-)-PG-9 O
through O
an O
increase O
in O
acetylcholine O
extracellular O
levels O
. O

In O
the O
antinociceptive O
and O
antiamnesic O
dose O
range O
, O
( O
+/-)-PG-9 O
did O
not O
impair O
mouse O
performance O
evaluated O
by O
the O
rota-rod O
test O
and O
Animex O
apparatus O
. O

-DOCSTART- O

Hyperbaric O
oxygen O
therapy O
for O
control O
of O
intractable O
cyclophosphamide-induced O
hemorrhagic B-PHE
cystitis I-PHE
. O

We O
report O
a O
case O
of O
intractable O
hemorrhagic B-PHE
cystitis I-PHE
due O
to O
cyclophosphamide O
therapy O
for O
Wegener's B-PHE
granulomatosis I-PHE
. O

Conservative O
treatment O
, O
including O
bladder O
irrigation O
with O
physiological O
saline O
and O
instillation O
of O
prostaglandin O
F2 O
alpha O
, O
failed O
to O
totally O
control O
hemorrhage B-PHE
. O

We O
then O
used O
hyperbaric O
oxygen O
at O
an O
absolute O
pressure O
of O
2 O
atm O
, O
5 O
days O
a O
week O
for O
8 O
consecutive O
weeks O
. O

The O
bleeding B-PHE
ceased O
completely O
by O
the O
end O
of O
treatment O
and O
the O
patient O
remained O
free O
of O
hematuria B-PHE
thereafter O
. O

No O
side O
effect O
was O
noted O
during O
the O
course O
of O
therapy O
. O

In O
future O
, O
this O
form O
of O
therapy O
can O
offer O
a O
safe O
alternative O
in O
the O
treatment O
of O
cyclophosphamide-induced O
hemorrhagic B-PHE
cystitis I-PHE
. O

-DOCSTART- O

Further O
studies O
on O
effects O
of O
irrigation O
solutions O
on O
rat O
bladders O
. O

Further O
studies O
on O
the O
effects O
of O
certain O
irrigating O
fluids O
on O
the O
rat O
bladder O
for O
18 O
hours O
are O
reported O
. O

The O
results O
have O
shown O
that O
the O
degradation O
product O
p-choloroaniline O
is O
not O
a O
significant O
factor O
in O
chlorhexidine-digluconate O
associated O
erosive O
cystitis B-PHE
. O

A O
high O
percentage O
of O
kanamycin-colistin O
and O
povidone-iodine O
irrigations O
were O
associated O
with O
erosive O
cystitis B-PHE
and O
suggested O
a O
possible O
complication O
with O
human O
usage O
. O

Picloxydine O
irrigations O
appeared O
to O
have O
a O
lower O
incidence O
of O
erosive O
cystitis B-PHE
but O
further O
studies O
would O
have O
to O
be O
performed O
before O
it O
could O
be O
recommended O
for O
use O
in O
urological O
procedures O
. O

-DOCSTART- O

Clinical O
experiences O
in O
an O
open O
and O
a O
double-blind O
trial O
. O

A O
total O
of O
sixty O
patients O
were O
trated O
with O
bromperidol O
first O
in O
open O
conditions O
( O
20 O
patients) O
, O
then O
on O
a O
double O
blind O
basis O
( O
40 O
patients O
) O
with O
haloperidol O
as O
the O
reference O
substance O
. O

The O
open O
study O
lasted O
for O
four O
weeks O
; O
the O
drug O
was O
administrated O
in O
the O
form O
of O
1 O
mg O
tablets O
. O

The O
daily O
dose O
( O
initial O
dose O
: O
1 O
mg O
; O
mean O
dose O
at O
the O
end O
of O
the O
trial O
: O
4.47 O
mg O
) O
was O
always O
administered O
in O
one O
single O
dose O
. O

Nineteen O
patients O
finished O
the O
trial O
, O
and O
in O
18 O
cases O
the O
therapeutic O
result O
was O
considered O
very O
good O
to O
good O
. O

These O
results O
were O
confirmed O
by O
statistical O
analysis O
. O

Nine O
patients O
exhibited O
mild O
to O
moderate O
extrapyramidal B-PHE
concomitant I-PHE
symptoms I-PHE
; O
no O
other O
side O
effects O
were O
observed O
. O

The O
results O
of O
detailed O
laboratory O
tests O
and O
evaluations O
of O
various O
quantitative O
and O
qualitative O
tolerability O
parameters O
were O
not O
indicative O
of O
toxic O
effects O
. O

In O
the O
double O
blind O
study O
with O
haloperidol O
, O
both O
substances O
were O
found O
to O
be O
highly O
effective O
in O
the O
treatment O
of O
psychotic B-PHE
syndromes I-PHE
belonging I-PHE
predominantly I-PHE
to I-PHE
the I-PHE
schizophrenia I-PHE
group I-PHE
. O

Certain O
clues O
, O
including O
the O
onset O
of O
action O
, O
seem O
to O
be O
indicative O
of O
the O
superiority O
of O
bromperidol O
. O

No O
differences O
were O
observed O
with O
respect O
to O
side O
effects O
and O
general O
tolerability O
. O

-DOCSTART- O

Curcumin O
ameliorates O
cognitive B-PHE
dysfunction I-PHE
and O
oxidative O
damage O
in O
phenobarbitone O
and O
carbamazepine O
administered O
rats O
. O

The O
antiepileptic O
drugs O
, O
phenobarbitone O
and O
carbamazepine O
are O
well O
known O
to O
cause O
cognitive B-PHE
impairment I-PHE
on O
chronic O
use O
. O

The O
increase O
in O
free O
radical O
generation O
has O
been O
implicated O
as O
one O
of O
the O
important O
mechanisms O
of O
cognitive B-PHE
impairment I-PHE
by O
antiepileptic O
drugs O
. O

Curcumin O
has O
shown O
antioxidant O
, O
anti-inflammatory O
and O
neuro-protective O
properties O
. O

Therefore O
, O
the O
present O
study O
was O
carried O
out O
to O
investigate O
the O
effect O
of O
chronic O
curcumin O
administration O
on O
phenobarbitone- O
and O
carbamazepine-induced O
cognitive B-PHE
impairment I-PHE
and O
oxidative O
stress O
in O
rats O
. O

Pharmacokinetic O
interactions O
of O
curcumin O
with O
phenobarbitone O
and O
carbamazepine O
were O
also O
studied O
. O

Vehicle/drugs O
were O
administered O
daily O
for O
21days O
to O
male O
Wistar O
rats O
. O

Passive O
avoidance O
paradigm O
and O
elevated O
plus O
maze O
test O
were O
used O
to O
assess O
cognitive O
function O
. O

At O
the O
end O
of O
study O
period O
, O
serum O
phenobarbitone O
and O
carbamazepine O
, O
whole O
brain O
malondialdehyde O
and O
reduced O
glutathione O
levels O
were O
estimated O
. O

The O
administration O
of O
phenobarbitone O
and O
carbamazepine O
for O
21days O
caused O
a O
significant O
impairment B-PHE
of I-PHE
learning I-PHE
and I-PHE
memory I-PHE
as O
well O
as O
an O
increased O
oxidative O
stress O
. O

Concomitant O
curcumin O
administration O
prevented O
the O
cognitive B-PHE
impairment I-PHE
and O
decreased O
the O
increased O
oxidative O
stress O
induced O
by O
these O
antiepileptic O
drugs O
. O

Curcumin O
co-administration O
did O
not O
cause O
any O
significant O
alteration O
in O
the O
serum O
concentrations O
of O
both O
phenobarbitone O
as O
well O
as O
carbamazepine O
. O

These O
results O
show O
that O
curcumin O
has O
beneficial O
effect O
in O
mitigating O
the O
deterioration B-PHE
of I-PHE
cognitive I-PHE
functions I-PHE
and O
oxidative O
damage O
in O
rats O
treated O
with O
phenobarbitone O
and O
carbamazepine O
without O
significantly O
altering O
their O
serum O
concentrations O
. O

The O
findings O
suggest O
that O
curcumin O
can O
be O
considered O
as O
a O
potential O
safe O
and O
effective O
adjuvant O
to O
phenobarbitone O
and O
carbamazepine O
therapy O
in O
preventing O
cognitive B-PHE
impairment I-PHE
associated O
with O
these O
drugs O
. O

-DOCSTART- O

Pyrrolidine O
dithiocarbamate O
protects O
the O
piriform O
cortex O
in O
the O
pilocarpine O
status B-PHE
epilepticus I-PHE
model O
. O

Pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
has O
a O
dual O
mechanism O
of O
action O
as O
an O
antioxidant O
and O
an O
inhibitor O
of O
the O
transcription O
factor O
kappa-beta O
. O

Both O
, O
production O
of O
reactive O
oxygen O
species O
as O
well O
as O
activation O
of O
NF-kappaB O
have O
been O
implicated O
in O
severe O
neuronal B-PHE
damage I-PHE
in O
different O
sub-regions O
of O
the O
hippocampus O
as O
well O
as O
in O
the O
surrounding O
cortices O
. O

The O
effect O
of O
PDTC O
on O
status B-PHE
epilepticus I-PHE
-associated O
cell O
loss O
in O
the O
hippocampus O
and O
piriform O
cortex O
was O
evaluated O
in O
the O
rat O
fractionated O
pilocarpine O
model O
. O

Treatment O
with O
150 O
mg/kg O
PDTC O
before O
and O
following O
status B-PHE
epilepticus I-PHE
significantly O
increased O
the O
mortality O
rate O
to O
100% O
. O

Administration O
of O
50 O
mg/kg O
PDTC O
( O
low-dose O
) O
did O
not O
exert O
major O
effects O
on O
the O
development O
of O
a O
status B-PHE
epilepticus I-PHE
or O
the O
mortality O
rate O
. O

In O
vehicle-treated O
rats O
, O
status B-PHE
epilepticus I-PHE
caused O
pronounced O
neuronal B-PHE
damage I-PHE
in O
the O
piriform O
cortex O
comprising O
both O
pyramidal O
cells O
and O
interneurons O
. O

Low-dose O
PDTC O
treatment O
almost O
completely O
protected O
from O
lesions O
in O
the O
piriform O
cortex O
. O

A O
significant O
decrease O
in O
neuronal O
density O
of O
the O
hippocampal O
hilar O
formation O
was O
identified O
in O
vehicle- O
and O
PDTC-treated O
rats O
following O
status B-PHE
epilepticus I-PHE
. O

In O
conclusion O
, O
the O
NF-kappaB O
inhibitor O
and O
antioxidant O
PDTC O
protected O
the O
piriform O
cortex O
, O
whereas O
it O
did O
not O
affect O
hilar O
neuronal B-PHE
loss I-PHE
. O

These O
data O
might O
indicate O
that O
the O
generation O
of O
reactive O
oxygen O
species O
and O
activation O
of O
NF-kappaB O
plays O
a O
more O
central O
role O
in O
seizure B-PHE
-associated O
neuronal B-PHE
damage I-PHE
in O
the O
temporal O
cortex O
as O
compared O
to O
the O
hippocampal O
hilus O
. O

However O
, O
future O
investigations O
are O
necessary O
to O
exactly O
analyze O
the O
biochemical O
mechanisms O
by O
which O
PDTC O
exerted O
its O
beneficial O
effects O
in O
the O
piriform O
cortex O
. O

-DOCSTART- O

Safety O
profile O
of O
a O
nicotine O
lozenge O
compared O
with O
that O
of O
nicotine O
gum O
in O
adult O
smokers O
with O
underlying O
medical O
conditions O
: O
a O
12-week O
, O
randomized O
, O
open-label O
study O
. O

BACKGROUND O
: O
Nicotine O
polacrilex O
lozenges O
deliver O
25% O
to O
27% O
more O
nicotine O
compared O
with O
equivalent O
doses O
of O
nicotine O
polacrilex O
gum O
. O

The O
increased O
nicotine O
exposure O
from O
the O
lozenge O
has O
raised O
questions O
about O
the O
relative O
safety O
of O
the O
lozenge O
and O
gum O
. O

OBJECTIVE O
: O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
safety O
profiles O
of O
the O
4-mg O
nicotine O
lozenge O
and O
4-mg O
nicotine O
gum O
in O
smokers O
with O
selected O
label-restricted O
diseases O
. O

METHODS O
: O
This O
was O
a O
multicenter O
, O
randomized O
, O
open-label O
study O
in O
adult O
smokers O
with O
heart B-PHE
disease I-PHE
, O
hypertension B-PHE
not O
controlled O
by O
medication O
, O
and/or O
diabetes B-PHE
mellitus I-PHE
. O

Patients O
were O
randomized O
in O
a O
1:1 O
ratio O
to O
receive O
the O
4-mg O
nicotine O
lozenge O
or O
4-mg O
nicotine O
gum O
. O

Safety O
assessments O
were O
made O
at O
baseline O
and O
at O
2, O
4, O
6, O
and O
12 O
weeks O
after O
the O
start O
of O
product O
use O
. O

RESULTS O
: O
Nine O
hundred O
one O
patients O
were O
randomized O
to O
treatment O
, O
447 O
who O
received O
the O
lozenge O
and O
454 O
who O
received O
the O
gum O
( O
safety O
population) O
. O

The O
majority O
were O
women O
(52.7%) O
. O

Patients' O
mean O
age O
was O
53.9 O
years O
, O
their O
mean O
weight O
was O
193.9 O
pounds O
, O
and O
they O
smoked O
a O
mean O
of O
25.2 O
cigarettes O
per O
day O
at O
baseline O
. O

Five O
hundred O
fifty-three O
patients O
, O
264 O
taking O
the O
lozenge O
and O
289 O
taking O
the O
gum O
, O
used O
the O
study O
product O
for O
> O
or O
=4 O
days O
per O
week O
during O
the O
first O
2 O
weeks O
( O
evaluable O
population) O
. O

The O
nicotine O
lozenge O
and O
nicotine O
gum O
were O
equally O
well O
tolerated O
, O
despite O
increased O
nicotine O
exposure O
from O
the O
lozenge O
. O

The O
incidence O
of O
adverse O
events O
in O
the O
2 O
groups O
was O
similar O
during O
the O
first O
2 O
weeks O
of O
product O
use O
( O
evaluation O
population O
: O
55.3% O
lozenge O
, O
54.7% O
gum) O
, O
as O
well O
as O
during O
the O
entire O
study O
( O
safety O
population O
: O
63.8% O
and O
58.6% O
, O
respectively) O
. O

Stratification O
of O
patients O
by O
sex O
, O
age O
, O
extent O
of O
concurrent O
smoking O
, O
extent O
of O
product O
use O
, O
and O
severity O
of O
adverse O
events O
revealed O
no O
clinically O
significant O
differences O
between O
the O
lozenge O
and O
gum O
. O

The O
most O
common O
adverse O
events O
were O
nausea B-PHE
( O
17.2% O
and O
16.1% O
; O
95% O
CI O
, O
-3.7 O
to O
6.0) O
, O
hiccups B-PHE
( O
10.7% O
and O
6.6% O
; O
95% O
CI O
, O
0.5 O
to O
7.8) O
, O
and O
headache B-PHE
( O
8.7% O
and O
9.9% O
; O
95% O
Cl O
, O
-5.0 O
to O
2.6) O
. O

Serious O
adverse O
events O
were O
reported O
in O
11 O
and O
13 O
patients O
in O
the O
respective O
groups O
. O

Fewer O
than O
6% O
of O
patients O
in O
either O
group O
were O
considered O
by O
the O
investigator O
to O
have O
a O
worsening O
of O
their O
overall O
disease O
condition O
during O
the O
study O
. O

The O
majority O
of O
patients O
( O
>60% O
) O
experienced O
no O
change O
in O
their O
disease O
status O
from O
baseline O
. O

CONCLUSION O
: O
The O
4-mg O
nicotine O
lozenge O
and O
4-mg O
nicotine O
gum O
had O
comparable O
safety O
profiles O
in O
these O
patients O
with O
label-restricted O
medical O
conditions O
. O

-DOCSTART- O

Development O
of O
levodopa-induced O
dyskinesias B-PHE
in O
parkinsonian B-PHE
monkeys O
may O
depend O
upon O
rate O
of O
symptom O
onset O
and/or O
duration O
of O
symptoms O
. O

Levodopa-induced O
dyskinesias B-PHE
( O
LIDs B-PHE
) O
present O
a O
major O
problem O
for O
the O
long-term O
management O
of O
Parkinson's B-PHE
disease I-PHE
( O
PD B-PHE
) O
patients O
. O

Due O
to O
the O
interdependence O
of O
risk O
factors O
in O
clinical O
populations O
, O
it O
is O
difficult O
to O
independently O
examine O
factors O
that O
may O
influence O
the O
development O
of O
LIDs B-PHE
. O

Using O
macaque O
monkeys O
with O
different O
types O
of O
MPTP-induced O
parkinsonism B-PHE
, O
the O
current O
study O
evaluated O
the O
degree O
to O
which O
rate O
of O
symptom O
progression O
, O
symptom O
severity O
, O
and O
response O
to O
and O
duration O
of O
levodopa O
therapy O
may O
be O
involved O
in O
the O
development O
of O
LIDs B-PHE
. O

Monkeys O
with O
acute O
( O
short-term O
) O
MPTP O
exposure O
, O
rapid O
symptom O
onset O
and O
short O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
developed O
dyskinesia B-PHE
between O
11 O
and O
24 O
days O
of O
daily O
levodopa O
administration O
. O

In O
contrast O
, O
monkeys O
with O
long-term O
MPTP O
exposure O
, O
slow O
symptom O
progression O
and/or O
long O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
were O
more O
resistant O
to O
developing O
LIDs B-PHE
(e.g. O
, O
dyskinesia B-PHE
developed O
no O
sooner O
than O
146 O
days O
of O
chronic O
levodopa O
administration) O
. O

All O
animals O
were O
similarly O
symptomatic O
at O
the O
start O
of O
levodopa O
treatment O
and O
had O
similar O
therapeutic O
responses O
to O
the O
drug O
. O

These O
data O
suggest O
distinct O
differences O
in O
the O
propensity O
to O
develop O
LIDs B-PHE
in O
monkeys O
with O
different O
rates O
of O
symptom O
progression O
or O
symptom O
durations O
prior O
to O
levodopa O
and O
demonstrate O
the O
value O
of O
these O
models O
for O
further O
studying O
the O
pathophysiology O
of O
LIDs B-PHE
. O

-DOCSTART- O

Propylthiouracil-induced O
perinuclear-staining O
antineutrophil O
cytoplasmic O
autoantibody-positive O
vasculitis B-PHE
in O
conjunction O
with O
pericarditis B-PHE
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
propylthiouracil-induced O
vasculitis B-PHE
manifesting O
with O
pericarditis B-PHE
. O

METHODS O
: O
We O
present O
the O
first O
case O
report O
of O
a O
woman O
with O
hyperthyroidism B-PHE
treated O
with O
propylthiouracil O
in O
whom O
a O
syndrome O
of O
pericarditis B-PHE
, O
fever B-PHE
, O
and O
glomerulonephritis B-PHE
developed O
. O

Serologic O
testing O
and O
immunologic O
studies O
were O
done O
, O
and O
a O
pericardial O
biopsy O
was O
performed O
. O

RESULTS O
: O
A O
25-year-old O
woman O
with O
Graves' B-PHE
disease I-PHE
had O
a O
febrile B-PHE
illness I-PHE
and O
evidence O
of O
pericarditis B-PHE
, O
which O
was O
confirmed O
by O
biopsy O
. O

Serologic O
evaluation O
revealed O
the O
presence O
of O
perinuclear-staining O
antineutrophil O
cytoplasmic O
autoantibodies O
( O
pANCA O
) O
against O
myeloperoxidase O
(MPO) O
. O

Propylthiouracil O
therapy O
was O
withdrawn O
, O
and O
she O
was O
treated O
with O
a O
1-month O
course O
of O
prednisone O
, O
which O
alleviated O
her O
symptoms O
. O

A O
literature O
review O
revealed O
no O
prior O
reports O
of O
pericarditis B-PHE
in O
anti-MPO O
pANCA-positive O
vasculitis B-PHE
associated O
with O
propylthio- O
uracil O
therapy O
. O

CONCLUSION O
: O
Pericarditis B-PHE
may O
be O
the O
initial O
manifestation O
of O
drug-induced O
vasculitis B-PHE
attributable O
to O
propylthio- O
uracil O
therapy O
. O

-DOCSTART- O

Two O
mouse O
lines O
selected O
for O
differential O
sensitivities O
to O
beta-carboline-induced O
seizures B-PHE
are O
also O
differentially O
sensitive O
to O
various O
pharmacological O
effects O
of O
other O
GABA(A O
) O
receptor O
ligands O
. O

Two O
mouse O
lines O
were O
selectively O
bred O
according O
to O
their O
sensitivity O
( O
BS O
line O
) O
or O
resistance O
( O
BR O
line O
) O
to O
seizures B-PHE
induced O
by O
a O
single O
i.p O
. O
injection O
of O
methyl O
beta-carboline-3-carboxylate O
(beta-CCM) O
, O
an O
inverse O
agonist O
of O
the O
GABA(A O
) O
receptor O
benzodiazepine O
site O
. O

Our O
aim O
was O
to O
characterize O
both O
lines' O
sensitivities O
to O
various O
physiological O
effects O
of O
other O
ligands O
of O
the O
GABA(A O
) O
receptor O
. O

We O
measured O
diazepam-induced O
anxiolysis O
with O
the O
elevated O
plus-maze O
test O
, O
diazepam-induced O
sedation O
by O
recording O
the O
vigilance O
states O
, O
and O
picrotoxin- O
and O
pentylenetetrazol-induced O
seizures B-PHE
after O
i.p O
. O
injections O
. O

Results O
presented O
here O
show O
that O
the O
differential O
sensitivities O
of O
BS O
and O
BR O
lines O
to O
beta-CCM O
can O
be O
extended O
to O
diazepam O
, O
picrotoxin O
, O
and O
pentylenetetrazol O
, O
suggesting O
a O
genetic O
selection O
of O
a O
general O
sensitivity O
and O
resistance O
to O
several O
ligands O
of O
the O
GABA(A O
) O
receptor O
. O

-DOCSTART- O

Analgesic O
effect O
of O
intravenous O
ketamine O
in O
cancer B-PHE
patients O
on O
morphine O
therapy O
: O
a O
randomized O
, O
controlled O
, O
double-blind O
, O
crossover O
, O
double-dose O
study O
. O
Pain B-PHE
not O
responsive O
to O
morphine O
is O
often O
problematic O
. O

Animal O
and O
clinical O
studies O
have O
suggested O
that O
N-methyl-D-aspartate O
( O
NMDA O
) O
antagonists O
, O
such O
as O
ketamine O
, O
may O
be O
effective O
in O
improving O
opioid O
analgesia O
in O
difficult O
pain B-PHE
syndromes O
, O
such O
as O
neuropathic B-PHE
pain I-PHE
. O

A O
slow O
bolus O
of O
subhypnotic O
doses O
of O
ketamine O
( O
0.25 O
mg/kg O
or O
0.50 O
mg/kg O
) O
was O
given O
to O
10 O
cancer B-PHE
patients O
whose O
pain B-PHE
was O
unrelieved O
by O
morphine O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
, O
double-dose O
study O
. O
Pain B-PHE
intensity O
on O
a O
0 O
to O
10 O
numerical O
scale O
; O
nausea B-PHE
and O
vomiting B-PHE
, O
drowsiness O
, O
confusion B-PHE
, O
and O
dry B-PHE
mouth I-PHE
, O
using O
a O
scale O
from O
0 O
to O
3 O
( O
not O
at O
all O
, O
slight O
, O
a O
lot O
, O
awful) O
; O
Mini-Mental O
State O
Examination O
( O
MMSE O
) O
(0-30) O
; O
and O
arterial O
pressure O
were O
recorded O
before O
administration O
of O
drugs O
( O
T0 O
) O
and O
after O
30 O
minutes O
(T30) O
, O
60 O
minutes O
(T60) O
, O
120 O
minutes O
(T120) O
, O
and O
180 O
minutes O
(T180) O
. O

Ketamine O
, O
but O
not O
saline O
solution O
, O
significantly O
reduced O
the O
pain B-PHE
intensity O
in O
almost O
all O
the O
patients O
at O
both O
doses O
. O

This O
effect O
was O
more O
relevant O
in O
patients O
treated O
with O
higher O
doses O
. O
Hallucinations B-PHE
occurred O
in O
4 O
patients O
, O
and O
an O
unpleasant O
sensation O
( O
empty O
head O
) O
was O
also O
reported O
by O
2 O
patients O
. O

These O
episodes O
reversed O
after O
the O
administration O
of O
diazepam O
1 O
mg O
intravenously O
. O

Significant O
increases O
in O
drowsiness O
were O
reported O
in O
patients O
treated O
with O
ketamine O
in O
both O
groups O
and O
were O
more O
marked O
with O
ketamine O
0.50 O
mg/kg O
. O

A O
significant O
difference O
in O
MMSE O
was O
observed O
at O
T30 O
in O
patients O
who O
received O
0.50 O
mg/kg O
of O
ketamine O
. O

Ketamine O
can O
improve O
morphine O
analgesia O
in O
difficult O
pain B-PHE
syndromes O
, O
such O
as O
neuropathic B-PHE
pain I-PHE
. O

However O
, O
the O
occurrence O
of O
central O
adverse O
effects O
should O
be O
taken O
into O
account O
, O
especially O
when O
using O
higher O
doses O
. O

This O
observation O
should O
be O
tested O
in O
studies O
of O
prolonged O
ketamine O
administration O
. O

-DOCSTART- O

Endocrine O
screening O
in O
1,022 O
men O
with O
erectile B-PHE
dysfunction I-PHE
: O
clinical O
significance O
and O
cost-effective O
strategy O
. O

PURPOSE O
: O
We O
reviewed O
the O
results O
of O
serum O
testosterone O
and O
prolactin O
determination O
in O
1,022 O
patients O
referred O
because O
of O
erectile B-PHE
dysfunction I-PHE
and O
compared O
the O
data O
with O
history O
, O
results O
of O
physical O
examination O
, O
other O
etiological O
investigations O
and O
effects O
of O
endocrine O
therapy O
to O
refine O
the O
rules O
of O
cost-effective O
endocrine O
screening O
and O
to O
pinpoint O
actual O
responsibility O
for O
hormonal O
abnormalities O
. O

MATERIALS O
AND O
METHODS O
: O
Testosterone O
and O
prolactin O
were O
determined O
by O
radioimmunoassay O
. O

Every O
patient O
was O
screened O
for O
testosterone O
and O
451 O
were O
screened O
for O
prolactin O
on O
the O
basis O
of O
low B-PHE
sexual I-PHE
desire I-PHE
, O
gynecomastia B-PHE
or O
testosterone O
less O
than O
4 O
ng./ml O
. O

Determination O
was O
repeated O
in O
case O
of O
abnormal O
first O
results O
. O

Prolactin O
results O
were O
compared O
with O
those O
of O
a O
previous O
personal O
cohort O
of O
1,340 O
patients O
with O
erectile B-PHE
dysfunction I-PHE
and O
systematic O
prolactin O
determination O
. O

Main O
clinical O
criteria O
tested O
regarding O
efficiency O
in O
hormone O
determination O
were O
low B-PHE
sexual I-PHE
desire I-PHE
, O
small O
testes O
and O
gynecomastia B-PHE
. O

Endocrine O
therapy O
consisted O
of O
testosterone O
heptylate O
or O
human O
chorionic O
gonadotropin O
for O
hypogonadism B-PHE
and O
bromocriptine O
for O
hyperprolactinemia B-PHE
. O

RESULTS O
: O
Testosterone O
was O
less O
than O
3 O
ng./ml O
. O
in O
107 O
patients O
but O
normal O
in O
40% O
at O
repeat O
determination O
. O

The O
prevalence O
of O
repeatedly O
low O
testosterone O
increased O
with O
age O
( O
4% O
before O
age O
50 O
years O
and O
9% O
50 O
years O
or O
older) O
. O

Two O
pituitary B-PHE
tumors I-PHE
were O
discovered O
after O
testosterone O
determination O
. O

Most O
of O
the O
other O
low O
testosterone O
levels O
seemed O
to O
result O
from O
nonorganic O
hypothalamic B-PHE
dysfunction I-PHE
because O
of O
normal O
serum O
luteinizing O
hormone O
and O
prolactin O
and O
to O
have O
only O
a O
small O
role O
in O
erectile B-PHE
dysfunction I-PHE
( O
definite O
improvement O
in O
only O
16 O
of O
44 O
[36%] O
after O
androgen O
therapy O
, O
normal O
morning O
or O
nocturnal O
erections O
in O
30% O
and O
definite O
vasculogenic O
contributions O
in O
42%) O
. O

Determining O
testosterone O
only O
in O
cases O
of O
low B-PHE
sexual I-PHE
desire I-PHE
or O
abnormal O
physical O
examination O
would O
have O
missed O
40% O
of O
the O
cases O
with O
low O
testosterone O
, O
including O
37% O
of O
those O
subsequently O
improved O
by O
androgen O
therapy O
. O

Prolactin O
exceeded O
20 O
ng./ml O
. O
in O
5 O
men O
and O
was O
normal O
in O
2 O
at O
repeat O
determination O
. O

Only O
1 O
prolactinoma B-PHE
was O
discovered O
. O

These O
data O
are O
lower O
than O
those O
we O
found O
during O
the O
last O
2 O
decades O
( O
overall O
prolactin O
greater O
than O
20 O
ng./ml O
. O
in O
1.86% O
of O
1,821 O
patients O
, O
prolactinomas B-PHE
in O
7, O
0.38%) O
. O

Bromocriptine O
was O
definitely O
effective O
in O
cases O
with O
prolactin O
greater O
than O
35 O
ng./ml O
. O

(8 O
of O
12 O
compared O
to O
only O
9 O
of O
22 O
cases O
with O
prolactin O
between O
20 O
and O
35 O
ng./ml.) O
. O

Testosterone O
was O
low O
in O
less O
than O
50% O
of O
cases O
with O
prolactin O
greater O
than O
35 O
ng./ml O
. O

CONCLUSIONS O
: O
Low O
prevalences O
and O
effects O
of O
low O
testosterone O
and O
high O
prolactin O
in O
erectile B-PHE
dysfunction I-PHE
cannot O
justify O
their O
routine O
determination O
. O

However O
, O
cost-effective O
screening O
strategies O
recommended O
so O
far O
missed O
40 O
to O
50% O
of O
cases O
improved O
with O
endocrine O
therapy O
and O
the O
pituitary B-PHE
tumors I-PHE
. O

We O
now O
advocate O
that O
before O
age O
50 O
years O
testosterone O
be O
determined O
only O
in O
cases O
of O
low B-PHE
sexual I-PHE
desire I-PHE
and O
abnormal O
physical O
examination O
but O
that O
it O
be O
measured O
in O
all O
men O
older O
than O
50 O
years O
. O

Prolactin O
should O
be O
determined O
only O
in O
cases O
of O
low B-PHE
sexual I-PHE
desire I-PHE
, O
gynecomastia B-PHE
and/or O
testosterone O
less O
than O
4 O
ng./ml O
. O

-DOCSTART- O

Thiopentone O
pretreatment O
for O
propofol O
injection O
pain B-PHE
in O
ambulatory O
patients O
. O

This O
study O
investigated O
propofol O
injection O
pain B-PHE
in O
patients O
undergoing O
ambulatory O
anaesthesia O
. O

In O
a O
randomized O
, O
double-blind O
trial O
, O
90 O
women O
were O
allocated O
to O
receive O
one O
of O
three O
treatments O
prior O
to O
induction O
of O
anaesthesia O
with O
propofol O
. O

Patients O
in O
Group O
C O
received O
2 O
ml O
normal O
saline O
, O
Group O
L, O
2 O
ml O
, O
lidocaine O
2% O
( O
40 O
mg O
) O
and O
Group O
T, O
2 O
ml O
thiopentone O
2.5% O
( O
50 O
mg) O
. O

Venous O
discomfort O
was O
assessed O
with O
a O
visual O
analogue O
scale O
( O
VAS O
) O
5-15 O
sec O
after O
commencing O
propofol O
administration O
using O
an O
infusion O
pump O
( O
rate O
1000 O
micrograms.kg-1.min-1) O
. O
Loss B-PHE
of I-PHE
consciousness I-PHE
occurred O
in O
60-90 O
sec O
. O

Visual O
analogue O
scores O
( O
mean O
+/- O
SD O
) O
during O
induction O
were O
lower O
in O
Groups O
L O
( O
3.3 O
+/- O
2.5 O
) O
and O
T O
( O
4.1 O
+/- O
2.7 O
) O
than O
in O
Group O
C O
( O
5.6 O
+/- O
2.3) O
; O
P O
= O
0.0031 O
. O

The O
incidence O
of O
venous O
discomfort O
was O
lower O
in O
Group O
L O
(76.6% O
; O
P O
< O
0.05 O
) O
than O
in O
Group O
C O
( O
100% O
) O
but O
not O
different O
from O
Group O
T O
(90%) O
. O

The O
VAS O
scores O
for O
recall O
of O
pain B-PHE
in O
the O
recovery O
room O
were O
correlated O
with O
the O
VAS O
scores O
during O
induction O
(r O
= O
0.7045 O
; O
P O
< O
0.0001) O
. O

Recovery O
room O
discharge O
times O
were O
similar O
: O
C O
( O
75.9 O
+/- O
19.4 O
min) O
; O
L O
73.6 O
+/- O
21.6 O
min) O
; O
T O
( O
77.1 O
+/- O
18.9 O
min) O
. O

Assessing O
their O
overall O
satisfaction O
, O
89.7% O
would O
choose O
propofol O
anaesthesia O
again O
. O

We O
conclude O
that O
lidocaine O
reduces O
the O
incidence O
and O
severity O
of O
propofol O
injection O
pain B-PHE
in O
ambulatory O
patients O
whereas O
thiopentone O
only O
reduces O
its O
severity O
. O

-DOCSTART- O

Comparison O
of O
i.v O
. O
glycopyrrolate O
and O
atropine O
in O
the O
prevention O
of O
bradycardia B-PHE
and O
arrhythmias B-PHE
following O
repeated O
doses O
of O
suxamethonium O
in O
children O
. O

The O
effectiveness O
of O
administration O
of O
glycopyrrolate O
5 O
and O
10 O
micrograms O
kg-1 O
and O
atropine O
10 O
and O
20 O
micrograms O
kg-1 O
i.v O
. O
immediately O
before O
the O
induction O
of O
anaesthesia O
, O
to O
prevent O
arrhythmia B-PHE
and O
bradycardia B-PHE
following O
repeated O
doses O
of O
suxamethonium O
in O
children O
, O
was O
studied O
. O

A O
control O
group O
was O
included O
for O
comparison O
with O
the O
lower O
dose O
range O
of O
glycopyrrolate O
and O
atropine O
. O

A O
frequency O
of O
bradycardia B-PHE
of O
50% O
was O
noted O
in O
the O
control O
group O
, O
but O
this O
was O
not O
significantly O
different O
from O
the O
frequency O
with O
the O
active O
drugs O
. O
Bradycardia B-PHE
( O
defined O
as O
a O
decrease O
in O
heart O
rate O
to O
less O
than O
50 O
beat O
min-1 O
) O
was O
prevented O
when O
the O
larger O
dose O
of O
either O
active O
drug O
was O
used O
. O

It O
is O
recommended O
that O
either O
glycopyrrolate O
10 O
micrograms O
kg-1 O
or O
atropine O
20 O
micrograms O
kg-1 O
i.v O
. O
should O
immediately O
precede O
induction O
of O
anaesthesia O
, O
in O
children O
, O
if O
the O
repeated O
administration O
of O
suxamethonium O
is O
anticipated O
. O

-DOCSTART- O

Reduction O
in O
caffeine O
toxicity B-PHE
by O
acetaminophen O
. O

A O
patient O
who O
allegedly O
consumed O
100 O
tablets O
of O
an O
over-the-counter O
analgesic O
containing O
sodium O
acetylsalicylate O
, O
caffeine O
, O
and O
acetaminophen O
displayed O
no O
significant O
CNS O
stimulation O
despite O
the O
presence O
of O
175 O
micrograms O
of O
caffeine O
per O
mL O
of O
serum O
. O

Because O
salicylates O
have O
been O
reported O
to O
augment O
the O
stimulatory O
effects O
of O
caffeine O
on O
the O
CNS O
, O
attention O
was O
focused O
on O
the O
possibility O
that O
the O
presence O
of O
acetaminophen O
( O
52 O
micrograms/mL O
) O
reduced O
the O
CNS O
toxicity B-PHE
of O
caffeine O
. O

Studies O
in O
DBA/2J O
mice O
showed O
that O
: O
1) O
pretreatment O
with O
acetaminophen O
( O
100 O
mg/kg O
) O
increased O
the O
interval O
between O
the O
administration O
of O
caffeine O
( O
300 O
to O
450 O
mg/kg O
IP O
) O
and O
the O
onset O
of O
fatal O
convulsions B-PHE
by O
a O
factor O
of O
about O
two O
; O
and O
2) O
pretreatment O
with O
acetaminophen O
( O
75 O
mg/kg O
) O
reduced O
the O
incidence O
of O
audiogenic O
seizures B-PHE
produced O
in O
the O
presence O
of O
caffeine O
( O
12.5 O
to O
75 O
mg/kg O
IP) O
. O

The O
frequency O
of O
sound-induced O
seizures B-PHE
after O
12.5 O
or O
25 O
mg/kg O
caffeine O
was O
reduced O
from O
50 O
to O
5% O
by O
acetaminophen O
. O

In O
the O
absence O
of O
caffeine O
, O
acetaminophen O
( O
up O
to O
300 O
mg/kg O
) O
did O
not O
modify O
the O
seizures B-PHE
induced O
by O
maximal O
electroshock O
and O
did O
not O
alter O
the O
convulsant O
dose O
of O
pentylenetetrezol O
in O
mice O
( O
tests O
performed O
by O
the O
Anticonvulsant O
Screening O
Project O
of O
NINCDS) O
. O

Acetaminophen O
( O
up O
to O
150 O
micrograms/mL O
) O
did O
not O
retard O
the O
incorporation O
of O
radioactive O
adenosine O
into O
ATP O
in O
slices O
of O
rat O
cerebral O
cortex O
. O

Thus O
the O
mechanism O
by O
which O
acetaminophen O
antagonizes O
the O
actions O
of O
caffeine O
in O
the O
CNS O
remains O
unknown O
. O

-DOCSTART- O

Flestolol O
: O
an O
ultra-short-acting O
beta-adrenergic O
blocking O
agent O
. O

Flestolol O
( O
ACC-9089 O
) O
is O
a O
nonselective O
, O
competitive O
, O
ultra-short-acting O
beta-adrenergic O
blocking O
agent O
, O
without O
any O
intrinsic O
sympathomimetic O
activity O
. O

Flestolol O
is O
metabolized O
by O
plasma O
esterases O
and O
has O
an O
elimination O
half-life O
of O
approximately O
6.5 O
minutes O
. O

This O
agent O
was O
well O
tolerated O
in O
healthy O
volunteers O
at O
doses O
up O
to O
100 O
micrograms/kg/min O
. O

In O
long-term O
infusion O
studies O
, O
flestolol O
was O
well O
tolerated O
at O
the O
effective O
beta-blocking O
dose O
(5 O
micrograms/kg/min O
) O
for O
up O
to O
seven O
days O
. O

Flestolol O
blood O
concentrations O
increased O
linearly O
with O
increasing O
dose O
and O
good O
correlation O
exists O
between O
blood O
concentrations O
of O
flestolol O
and O
beta-adrenergic O
blockade O
. O

Flestolol O
produced O
a O
dose-dependent O
attenuation O
of O
isoproterenol-induced O
tachycardia B-PHE
. O

Electrophysiologic O
and O
hemodynamic O
effects O
of O
flestolol O
are O
similar O
to O
those O
of O
other O
beta O
blockers O
. O

In O
contrast O
with O
other O
beta O
blockers O
, O
flestolol-induced O
effects O
reverse O
rapidly O
( O
within O
30 O
minutes O
) O
following O
discontinuation O
because O
of O
its O
short O
half-life O
. O

Flestolol O
effectively O
reduced O
heart O
rate O
in O
patients O
with O
supraventricular B-PHE
tachyarrhythmia I-PHE
. O

In O
patients O
with O
unstable B-PHE
angina I-PHE
, O
flestolol O
infusion O
was O
found O
to O
be O
safe O
and O
effective O
in O
controlling O
chest B-PHE
pain I-PHE
. O

It O
is O
concluded O
that O
flestolol O
is O
a O
potent O
, O
well-tolerated O
, O
ultra-short-acting O
beta-adrenergic O
blocking O
agent O
. O

Use O
of O
flestolol O
in O
the O
critical O
care O
setting O
is O
currently O
undergoing O
investigation O
. O

-DOCSTART- O

Adverse O
effect O
of O
the O
calcium O
channel O
blocker O
nitrendipine O
on O
nephrosclerosis B-PHE
in O
rats O
with O
renovascular B-PHE
hypertension I-PHE
. O

The O
effect O
of O
a O
6-week O
treatment O
with O
the O
calcium O
channel O
blocker O
nitrendipine O
or O
the O
angiotensin O
converting O
enzyme O
inhibitor O
enalapril O
on O
blood O
pressure O
, O
albuminuria B-PHE
, O
renal O
hemodynamics O
, O
and O
morphology O
of O
the O
nonclipped O
kidney O
was O
studied O
in O
rats O
with O
two-kidney O
, O
one O
clip O
renovascular B-PHE
hypertension I-PHE
. O

Six O
weeks O
after O
clipping O
of O
one O
renal O
artery O
, O
hypertensive B-PHE
rats O
( O
178 O
+/- O
4 O
mm O
Hg O
) O
were O
randomly O
assigned O
to O
three O
groups O
: O
untreated O
hypertensive B-PHE
controls O
(n O
= O
8) O
, O
enalapril-treated O
(n O
= O
8) O
, O
or O
nitrendipine-treated O
(n O
= O
10) O
. O

Sham-operated O
rats O
served O
as O
normotensive O
controls O
( O
128 O
+/- O
3 O
mm O
Hg O
, O
n O
= O
8) O
. O

After O
6 O
weeks O
of O
treatment O
, O
renal O
hemodynamics O
( O
glomerular O
filtration O
rate O
and O
renal O
plasma O
flow O
) O
were O
measured O
in O
the O
anesthetized O
rats O
. O

Renal O
tissue O
was O
obtained O
for O
determination O
of O
glomerular O
size O
and O
sclerosis O
. O

Enalapril O
but O
not O
nitrendipine O
reduced O
blood O
pressure O
significantly O
. O

After O
6 O
weeks O
of O
therapy O
, O
glomerular O
filtration O
rate O
was O
not O
different O
among O
the O
studied O
groups O
. O

Renal O
plasma O
flow O
increased O
, O
but O
albumin O
excretion O
and O
glomerulosclerosis B-PHE
did O
not O
change O
after O
enalapril O
treatment O
. O

In O
contrast O
, O
in O
the O
nitrendipine-treated O
group O
albuminuria B-PHE
increased O
from O
12.8 O
+/- O
2 O
progressively O
to O
163 O
+/- O
55 O
compared O
with O
19.2 O
+/- O
9 O
mg/24 O
hr O
in O
the O
hypertensive B-PHE
controls O
. O

Furthermore O
, O
glomerulosclerosis B-PHE
index O
was O
significantly O
increased O
in O
the O
nitrendipine-treated O
group O
compared O
with O
the O
hypertensive B-PHE
controls O
( O
0.38 O
+/- O
0.1 O
versus O
0.13 O
+/- O
0.04) O
. O

In O
addition O
, O
glomerular O
size O
was O
higher O
in O
the O
nitrendipine-treated O
group O
( O
14.9 O
+/- O
0.17 O
10(-3 O
) O
mm2 O
) O
but O
lower O
in O
the O
enalapril-treated O
group O
( O
11.5 O
+/- O
0.15 O
10(-3 O
) O
mm2 O
) O
compared O
with O
the O
hypertensive B-PHE
controls O
( O
12.1 O
+/- O
0.17 O
10(-3 O
) O
mm2).(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

-DOCSTART- O

Treatment O
of O
tinnitus B-PHE
by O
intratympanic O
instillation O
of O
lignocaine O
( O
lidocaine O
) O
2 O
per O
cent O
through O
ventilation O
tubes O
. O
Idiopathic B-PHE
subjective I-PHE
tinnitus I-PHE
( O
IST B-PHE
) O
is O
one O
of O
the O
most O
obscure O
otological O
pathologies O
. O

This O
paper O
presents O
the O
results O
of O
treating O
IST B-PHE
by O
intratympanic O
instillation O
of O
lignocaine O
( O
lidocaine O
) O
2 O
per O
cent O
through O
a O
grommet O
, O
for O
five O
weekly O
courses O
. O

Fifty-two O
patients O
suffering O
from O
intractable O
tinnitus B-PHE
entered O
this O
therapeutic O
trial O
, O
but O
only O
nine O
finished O
all O
five O
courses O
. O

In O
one O
patient O
, O
the O
tinnitus B-PHE
was O
almost O
completely O
abolished O
, O
but O
in O
all O
the O
nine O
patients O
the O
decompensated O
tinnitus B-PHE
changed O
to O
a O
compensated O
one O
. O

We O
suggest O
this O
mode O
of O
treatment O
for O
patients O
that O
were O
previously O
treated O
by O
drugs O
, O
acupuncture O
and O
biofeedback O
, O
with O
disappointing O
results O
. O

Patients O
should O
be O
warned O
about O
the O
side O
effects O
of O
vertigo B-PHE
and O
vomiting B-PHE
, O
which O
subsides O
gradually O
with O
every O
new O
instillation O
, O
and O
that O
the O
tinnitus B-PHE
may O
not O
disappear O
but O
will O
be O
alleviated O
, O
enabling O
them O
to O
cope O
more O
easily O
with O
the O
disease O
and O
lead O
a O
more O
normal O
life O
. O

-DOCSTART- O

Perhexiline O
maleate O
and O
peripheral B-PHE
neuropathy I-PHE
. O
Peripheral B-PHE
neuropathy I-PHE
has O
been O
noted O
as O
a O
complication O
of O
therapy O
with O
perhexiline O
maleate O
, O
a O
drug O
widely O
used O
in O
France O
( O
and O
in O
clinical O
trials O
in O
the O
United O
States O
) O
for O
the O
prophylactic O
treatment O
of O
angina B-PHE
pectoris I-PHE
. O

In O
24 O
patients O
with O
this O
complication O
, O
the O
marked O
slowing O
of O
motor O
nerve O
conduction O
velocity O
and O
the O
electromyographic O
changes O
imply O
mainly O
a O
demyelinating B-PHE
disorder I-PHE
. O

Improvement O
was O
noted O
with O
cessation O
of O
therapy O
. O

In O
a O
few O
cases O
the O
presence O
of O
active O
denervation O
signified O
a O
poor O
prognosis O
, O
with O
only O
slight O
improvement O
. O

The O
underlying O
mechanism O
causing O
the O
neuropathy B-PHE
is O
not O
yet O
fully O
known O
, O
although O
some O
evidence O
indicates O
that O
it O
may O
be O
a O
lipid O
storage O
process O
. O

-DOCSTART- O

Effect O
of O
humoral O
modulators O
of O
morphine-induced O
increase B-PHE
in I-PHE
locomotor I-PHE
activity I-PHE
of O
mice O
. O

The O
effect O
of O
humoral O
modulators O
on O
the O
morphine-induced O
increase B-PHE
in I-PHE
locomotor I-PHE
activity I-PHE
of O
mice O
was O
studied O
. O

The O
subcutaneous O
administration O
of O
10 O
mg/kg O
of O
morphine-HC1 O
produced O
a O
marked O
increase B-PHE
in I-PHE
locomotor I-PHE
activity I-PHE
in O
mice O
. O

The O
morphine-induced O
hyperactivity B-PHE
was O
potentiated O
by O
scopolamine O
and O
attenuated O
by O
physostigmine O
. O

In O
contrast O
, O
both O
methscopolamine O
and O
neostigmine O
, O
which O
do O
not O
penetrate O
the O
blood-brain O
barrier O
, O
had O
no O
effect O
on O
the O
hyperactivity B-PHE
produced O
by O
morphine O
. O

Pretreatment O
of O
mice O
with O
alpha-methyltyrosine O
( O
20 O
mg/kg O
i.p. O
, O
one O
hour) O
, O
an O
inhibitor O
of O
tyrosine O
hydroxylase O
, O
significantly O
decreased O
the O
activity-increasing O
effects O
of O
morphine O
. O

On O
the O
other O
hand O
, O
pretreatment O
with O
p-chlorophenylalamine O
(3 O
X O
320 O
mg/kg O
i.p. O
, O
24 O
hr) O
, O
a O
serotonin O
depletor O
, O
caused O
no O
significant O
change O
in O
the O
hyperactivity B-PHE
. O

The O
study O
suggests O
that O
the O
activity-increasing O
effects O
of O
morphine O
are O
mediated O
by O
the O
release O
of O
catecholamines O
from O
adrenergic O
neurons O
in O
the O
brain O
. O

And O
the O
results O
are O
consistent O
with O
the O
hypothesis O
that O
morphine O
acts O
by O
retarding O
the O
release O
of O
acetylcholine O
at O
some O
central O
cholinergic O
synapses O
. O

It O
is O
also O
suggested O
from O
collected O
evidence O
that O
the O
activity-increasing O
effects O
of O
morphine O
in O
mice O
are O
mediated O
by O
mechanisms O
different O
from O
those O
which O
mediate O
the O
activity-increasing O
effects O
of O
morphine O
in O
rats O
. O

-DOCSTART- O

Mechanisms O
of O
FK O
506-induced O
hypertension B-PHE
in O
the O
rat O
. O
-Tacrolimus O
( O
FK O
506 O
) O
is O
a O
powerful O
, O
widely O
used O
immunosuppressant O
. O

The O
clinical O
utility O
of O
FK O
506 O
is O
complicated O
by O
substantial O
hypertension B-PHE
and O
nephrotoxicity B-PHE
. O

To O
clarify O
the O
mechanisms O
of O
FK O
506-induced O
hypertension B-PHE
, O
we O
studied O
the O
chronic O
effects O
of O
FK O
506 O
on O
the O
synthesis O
of O
endothelin-1 O
(ET-1) O
, O
the O
expression O
of O
mRNA O
of O
ET-1 O
and O
endothelin-converting O
enzyme-1 O
(ECE-1) O
, O
the O
endothelial O
nitric O
oxide O
synthase O
( O
eNOS O
) O
activity O
, O
and O
the O
expression O
of O
mRNA O
of O
eNOS O
and O
C-type O
natriuretic O
peptide O
( O
CNP O
) O
in O
rat O
blood O
vessels O
. O

In O
addition O
, O
the O
effect O
of O
the O
specific O
endothelin O
type O
A O
receptor O
antagonist O
FR O
139317 O
on O
FK O
506-induced O
hypertension B-PHE
in O
rats O
was O
studied O
. O

FK O
506 O
, O
5 O
mg O
. O

kg-1 O
. O

d-1 O
given O
for O
4 O
weeks O
, O
elevated O
blood O
pressure O
from O
102+/-13 O
to O
152+/-15 O
mm O
Hg O
and O
increased O
the O
synthesis O
of O
ET-1 O
and O
the O
levels O
of O
ET-1 O
mRNA O
in O
the O
mesenteric O
artery O
( O
240% O
and O
230% O
, O
respectively) O
. O

Little O
change O
was O
observed O
in O
the O
expression O
of O
ECE-1 O
mRNA O
and O
CNP O
mRNA O
. O

FK O
506 O
decreased O
eNOS O
activity O
and O
the O
levels O
of O
eNOS O
mRNA O
in O
the O
aorta O
( O
48% O
and O
55% O
, O
respectively) O
. O

The O
administration O
of O
FR O
139317 O
( O
10 O
mg O
. O
kg-1 O
. O
d-1 O
) O
prevented O
FK O
506-induced O
hypertension B-PHE
in O
rats O
. O

These O
results O
indicate O
that O
FK O
506 O
may O
increase O
blood O
pressure O
not O
only O
by O
increasing O
ET-1 O
production O
but O
also O
by O
decreasing O
NO O
synthesis O
in O
the O
vasculature O
. O